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Sphingosine kinase (SphK) is a key enzyme in the sphingolipid metabolic pathway
responsible for phosphorylating sphingosine into sphingosine-1-phosphate (S1P). S1P
is an important bioactive signalling molecule that has both intracellular and
extracellular functions, mediating cellular events such as calcium mobilisation,
proliferation, migration, and cytokine production. Increasingly, roles of SphK/S1P
have been demonstrated in several inflammatory responses and pathophysiologic
conditions, rendering these molecules an excellent target of investigation in various
disease models. Of interest to our research are the chronic inflammatory diseases
Asthma and Rheumatoid Arthritis (RA).
For asthma, the role of SphK in a murine model of allergic asthma was examined. In
mice previously sensitized to OVA, intraperitoneal administration of N,N-
dimethylsphingosine (DMS), a potent SphK inhibitor, significantly reduced the total
inflammatory cell infiltrate and eosinophilia and the IL-4, IL-5, and eotaxin levels in
bronchoalveolar lavage fluid in response to inhaled OVA challenge. In addition, DMS
significantly suppressed OVA-induced inflammatory infiltrates and mucus production
in the lungs, and airway hyperresponsiveness to methacholine in a dose-dependent
manner. OVA-induced lymphocyte proliferation and IL-4 and IL-5 secretion were
reduced in thoracic lymph node cultures from DMS-treated mice. Moreover, similar
reduction in inflammatory infiltrates, BAL IL-4, IL-5, eotaxin, and serum OVA-
specific IgE levels was observed in mice with SphK1 knock-down via small
interfering RNA approach. Together, these data demonstrate the therapeutic potential
of SphK modulation in allergic airways disease.
XAs for RA, we observed that levels of S1P in the synovial fluid of RA patients were
significantly higher than those of osteoarthritis patients. In addition, DMS
significantly reduced the levels of pro-inflammatory cytokines in cell-contact assays
using both Jurkat-U937 cells and RA PBMCs. In a murine collagen-induced arthritis
(CIA) model, intraperitoneal administration of DMS significantly inhibited disease
severity and reduced articular inflammation and joint destruction. Treatment of DMS
also down-regulated serum levels IL-6, TNF-α, IFN-γ, S1P, and IgG1 and IgG2a anti-
collagen antibodies. Furthermore, DMS-treated mice also displayed suppressed pro-
inflammatory cytokines production in response to type II collagen in vitro.
Next, we studied the role of SphK1 versus SphK2 in CIA by employing the siRNA
knockdown approach. We showed that prophylactic intraperitoneal administration of
SphK1 siRNA significantly reduced the incidence, disease severity and articular
inflammation compared with control siRNA recipients. Treatment of SphK1 siRNA
also down-regulated serum levels of S1P, IL-6, TNF-α, IFN-γ, and IgG2a anti-
collagen antibody. Ex vivo analysis demonstrated significant suppression of collagen-
specific pro-inflammatory/Th1 cytokine release in SphK1 siRNA treated mice.
Interestingly, mice administered with SphK2 siRNA develop more aggressive disease,
higher serum levels of pro-inflammatory cytokines and higher production of these
cytokines in response to collagen in vitro when compared with control siRNA
recipients. Together, these results demonstrate the distinct immunomodulatory roles
of SphK1 and SphK2 in the development of inflammatory arthritis by regulating the
release of pro-inflammatory cytokines and T cell responses. These findings raise the
possibility that drugs specifically target SphK1 activity may play a beneficial role in
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‘Subtle as Sphinx ... ’
William Shakespeare, Love’s Labour’s Lost, Act IV, Scene iii.
Sphingolipids represent a major class of lipids which are ubiquitously expressed in
eukaryotic cell membranes. First discovered by J. L. W. Thudichum in 1876, who
named the chemical backbone of sphingolipids after the Greek mythological beast,
Sphinx, for their enigmatic ‘Sphinx-like’ properties, sphingolipids are characterised
by their sphingoid backbone, and primary structural roles in membrane formation.
More recently, sphingolipids have also been reported to dynamically cluster with
sterols to form lipid microdomains or rafts, which function as hubs for effective signal
transduction and protein sorting (1). Apart from their structural functions, they have
emerged as the source of important signalling molecules (2), potentially involved in
pathophysiological processes (3, 4). Following stimulation of various plasma
membrane receptors, an enzymatic cascade (Fig. 1.1) is activated and these lipids are
rapidly metabolized into sphingolipid metabolites, such as ceramide and sphingosine-
1-phosphate (S1P). Belonging to a new class of potent bioactive molecules, ceramide
and S1P have been shown to be involved in a variety of cellular processes, including
cell differentiation, apoptosis and proliferation (5-8).
1.1.1 Sphingolipid Metabolism
The sphingolipid metabolism pathway is highly complex, with several points of
modulation and regulation (Fig. 1.1). There are two routes of entry into the pathway,
3both of which converge on the generation of ceramide. The de novo pathway takes
place in the endoplasmic reticulum. It begins with the condensation of serine and
palmitoyl-CoA, leading to the generation of ceramide. The salvage pathway, which
appears to be the major route for agonist-induced generation of ceramide, is initiated
by the hydrolysis of sphingomyelin, the major membrane sphingolipid. Ceramide is
formed when sphingomyelin is hydrolyzed by sphingomyelinases and has been
implicated in apoptosis (4). Ceramide can be further metabolised by ceramidases to
yield the single fatty-chain sphingosine (5). Sphingosine can be phosphorylated by
sphingosine kinases (SphKs), to generate sphingosine-1-phosphate (S1P) (2-8).
Metabolism of S1P is mediated either by reversible dephosphorylation to sphingosine
by S1P phosphohydrolase, or by irreversible cleavage to ethanolamine phosphate and
hexadecanal by S1P lyase (9). SphK is thus a key enzyme in sphingolipid metabolism,
as it has been proposed to function as a thermostat that modulates the relative levels
of S1P and ceramide, which determines cell fate (10).
4Figure 1.1 Sphingolipid metabolic pathway
There are two routes of entry into the sphingolipid metabolic pathway: the de novo
pathway, which begins with the condensation of serine and palmitoyl-CoA, and the
salvage pathway, with the hydrolysis of the major membrane sphingolipid,
sphingomyelin. Both pathways converge on the generation of ceramide, which is
further metabolised to other bioactive molecules. The enzyme sphingosine kinase
(SphK) predominantly phosphorylates sphingosine into sphingosine-1-phosphate
(S1P), which is either cleaved by S1P lyase to hexadecanal and ethanolamine-1-
phosphate, or dephosphorylated to sphingosine by S1P phosphohydrolase.
Adapted from Bartke, N. and Hannun, Y.A. 2009. J. lipid Res. 50:S91-6
51.1.2 Sphingosine-1-Phosphate
Bioactive lysophospholipid, S1P, is a unique signalling molecule that has the ability
to act as an intracellular second messenger as well as extracellular stimulus through
specific G-protein coupled receptors (GPCRs) (7, 8, 11) To date, five S1P receptors,
S1P1-5 (12-15), belonging to the endothelial-differentiating gene (EDG) family have
been discovered. Binding of S1P to these receptors triggers a wide range of cellular
responses including proliferation, enhanced extracellular matrix assembly, stimulation
of adherent junctions, formation of actin stress fibres, and inhibition of apoptosis (15-
19). These receptors mediate their diverse cellular functions through differential
coupling to various heterotrimeric G-proteins and through heterogeneity in their
expression patterns (20). S1P has also been proposed to play an intracellular role as a
second messenger after observations that stimulation of various plasma membrane
receptors, such as the platelet-derived growth factor receptor (PDGF) (21, 22), FcγRI
and FcεRI antigen receptors (23-25), the fMLP receptor (26), the C5a receptor (27,
28), and tumour necrosis factor (TNF)-α receptor (29) trigger rapid production of S1P
through SphK activation. Moreover, inhibition of SphK strongly reduced cellular
events triggered by these receptors, such as receptor-triggered DNA synthesis,
calcium (Ca2+) mobilisation and vesicular trafficking (21-26).
1.1.3 Sphingosine Kinase 1 and 2
Sphingosine kinase is a key enzyme in the sphingolipid metabolic pathway as it
provides an essential checkpoint that regulates the relative levels of ceramide,
sphingosine, and S1P (10). To date, two mammalian SphKs have been cloned,
6sequenced and characterised. These kinases are encoded by two genes, SphK1 (10, 30,
31), and SphK2 (32). Human SphK1 localises to chromosome 17 (17q25.2), whereas
SphK2 maps to chromosome 19 (19q13.2). Although the two mammalian isoforms
possess five evolutionarily conserved domains found in all SphKs and are highly
similar in amino acid sequence, they differ in kinetic properties and also in temporal
and spatial distribution, implying that they may have distinct physiological functions.
SphK1 mRNA is most highly expressed in the brain, heart, thymus, spleen, kidney,
and lung (30) whereas SphK2 is highest in the kidney and the liver (32). Sphingosine
kinases activities reside mostly in the soluble extracts of cells, although a small
portion of the activities has been associated with the membrane component as well. In
addition, they appear to be highly specific in their substrate preference. Both SphK1
and SphK2 are capable of phosphorylating erythrosphingosine, dihydrosphingosine
and phytosphingosine; however, no other phospholipids appear to be significantly
phosphorylated by these enzymes (10, 30, 31). Although the SphK could be inhibited
by a number of compounds, the best known chemical inhibitors are analogues of
sphingosine, such as DL-threodihydrosphingosine (DHS) and N, N-
dimethylsphingosine (DMS) (33, 34).
1.1.4 Mechanism of SphKs activation in mammalian cells
Stimulation of various plasma membrane receptors can trigger the activation of
SphKs. Growth factors, such as epidermal growth factor (EGF) (35), PDGF (22),
nerve growth factor (NGF) (36) and vascular endothelial growth factor (VEGF) (37),
have been shown to increase SphK activity. Vitamin D3 and serum are also activators
of SphK (38, 39). Furthermore, cytokines such as TNF-α (29), chemotactic peptides
7such as fMLP and C5a, as well as Fc receptors, FcεRI and FcγRI, have been reported
to activate SphK activity in different immune–effector cells (11, 23, 25-28, 40, 41).
1.2 S1P signalling in the immune responses
S1P is synthesised in most cells, but is dephosphorylated by S1P phosphatases or
irreversibly degraded by intracellular S1P lyase (42-45). So, in most tissues, including
lymphoid tissue, S1P levels are extremely low. Notable exceptions are the blood,
where S1P levels are in the low-micromolar range and are mainly contributed by
erythrocytes, and the lymph, where S1P levels are in the hundred-nanomolar range
(46, 47). There are diverse mechanisms for the regulation of the secretion as well as
levels of S1P in the circulatory fluids and tissue following an immune challenge. This
apparent redundancy emphasises the physiological importance of S1P and the
significance of the S1P gradient between circulatory fluid and tissue in vivo.
1.2.1 S1P and immune cell trafficking
S1P plays a vital role in both the homing of immune cells to lymphoid organs, and in
controlling their egress into the blood and lymph. An important factor driving such
egression is the S1P gradient that exists between the tissues (which have low S1P
levels) and the blood/lymph (which have high S1P levels). One of the five S1P
receptors, S1P1, has been shown to be involved in the egression of B and T cells from
the peripheral lymphoid organs (48), and for the exit of mature T cells from the
thymus (49). Furthermore, it has been shown that S1P plays a central role leukocyte
chemotaxis in purified human peripheral blood neutrophils, eosinophil, monocytes
8and macrophages. (26-28, 50) During inflammation, S1P level is dramatically
increased in the tissue where the inflammation is taking. This increase in S1P level
could promote the recruitment and retention of lymphocytes in the inflamed tissues.
1.2.2 S1P and vascular barrier integrity
Vascular endothelium is a complex tissue that forms a semi-permeable barrier
between the intravascular fluid and the interstitium of various organs. Integrity of the
endothelial cell (EC) monolayer is essential for homeostasis, and various pathological
conditions, such as acute lung injury and atherogenesis, can lead to the disruption of
this barrier. S1P has been previously characterised to possess the ability to enhance
endothelial cell barrier integrity (51). Both S1P1 and S1P3 receptors are present on the
ECs (52-54). S1P-induced EC barrier integrity enhancement occurs primarily via
S1P1 with subsequent signalling through the G-protein dependent pathways.
1.2.3 SphK/S1P and cell adhesion molecules expression
In another study, TNF-α stimulation of endothelial cells has been shown to rapidly
stimulate SphK activity and S1P generation, leading to the expression of cell adhesion
molecules, vascular cell adhesion molecule 1 (VCAM-1) and E-selectin (41). The
importance of SphK activity in TNF-α – induced cell adhesion molecule expression
was demonstrated through the use of a pharmacological inhibitor of SphK, DMS. This
inhibitor strongly inhibited the TNF-α induced activation of ERK and NF-κB, as well
as expression of cell adhesion molecules (41).
91.3 Role of SphKs in specialised immune and other inflammatory cells
1.3.1 Role of SphK in lymphocytes
It has been observed that by overexpressing SphK1 in the Jurkat T cells, enhanced
SphK activity and S1P level promote cell survival and protect the cells against
apoptosis induced by ceramide or Fas (55). S1P treatment increased survival of B
cells and T cells by activating the phosphatidylinositol 3-kinase (PI3K) and lipid-
dependent AKT pathway (56). In CD4 T cells isolated from mouse spleen, S1P
treatment suppressed T cell proliferation induced by T-cell receptor ligation.
Furthermore, S1P decreased CD4 T cell production of IFN- and interleukin- (IL-) 4
without affecting IL-2 (57). Anti-CD3 plus anti-CD28 induced human peripheral
blood T-cell proliferation was inhibited by the addition of 0.1 to 10 µM S1P. On the
contrary, S1P enhanced IL-2 and IFN-γ secretion by the T cells, indicating the
differential effects of S1P on polyclonal T-cell proliferation and cytokine secretion
(58).
Recent studies have shown that S1P receptors, particularly S1P1, are critical for egress
of lymphocyte from the lymph organs (46, 48, 49). Matloubian et al. showed that in
mice whose haematopoietic cells lack a single S1P receptor (S1P1; also known as
Edg1), mature T cells were unable to exit the thymus. Although B cells were present
in peripheral lymphoid organs, they were severely deficient in blood and lymph.
Adoptive cell transfer of thymocytes from S1P1-/- or wild-type (WT) fetal liver
chimaeras established an intrinsic requirement for S1P1 in T and B cells for lymphoid
organ egress. Furthermore, S1P1-dependent chemotactic responsiveness was strongly
upregulated in T-cell development before exit from the thymus, whereas S1P1 was
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downregulated during peripheral lymphocyte activation, and this was associated with
retention in lymphoid organs. FTY720, also known as Fingolimod, is a structural
analogue of sphingosine. Upon phosphorylation by SphK2, it can act as a potent
agonist on four of the S1P receptors. FTY720 treatment downregulated S1P1, creating
a temporary pharmacological S1P1-null state in lymphocytes, providing an
explanation for the mechanism of FTY720-induced lymphocyte sequestration. These
findings established that S1P1 is essential for lymphocyte recirculation and that it
regulated egress from both thymus and peripheral lymphoid organs (48). In T cell-
specific S1P1 knock-out mouse model, the egress of mature T cells into the periphery
was blocked. The expression of the S1P1 receptor was up-regulated in normal mature
thymocytes, and its deletion altered the chemotactic responses of thymocytes to S1P.
This indicated that the expression of the S1P1 receptors on T cells controls their exit
from the thymus and entry into the blood and, thus, has a central role in regulating the
numbers of peripheral T cells (49). Agonist of S1P receptors can lead to down-
regulation of these receptors and subsequent sequestration of lymphocytes in
secondary lymphatic tissues (48, 59).
A recent finding by Chi’s group demonstrated that S1P1 receptor impedes the
development and function of Treg cells via the Akt-mTOR kinase pathway, thus S1P1
contributes to adaptive immune responses (60). Using S1P1 knockout and transgenic
mice overexpressing S1P1, Chi was able to show that S1P1 inhibits thymic
development of Treg cells development by blocking the differentiation of precursors
CD4+CD25+Foxp3- population into mature Foxp3-expressing Treg cells. Moreover,
S1P1-transgenic Treg cells exhibited impaired suppressive activity in vitro and in vivo,
leading to the development of spontaneous autoimmunity in these transgenic mice.
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Furthermore, it has been suggested that mouse SphK2 associates with the
cytoplasmic region of IL-12 receptor beta chain and it is likely to positively modulate
the effect of IL-12 on T cell response which leads to the generation of IFN- in the
mouse (61).
1.3.2 Th17 and SphK/S1P
Th17 recently has been designated to a unique subset of CD4 T cells characterised by
production of IL-17 (62, 63). IL-17 has been suggested to be an important cytokine in
the pathogenesis of inflammatory and autoimmune disease condition in both animals
and humans (64). Studies have shown that the key to Th17 differentiation in the
mouse is the combination of transforming growth factor- (TGF-) and IL-6 (65-67),
and expands up to full potential in the presence of IL-23 (68, 69). In addition, TNF-
and IL-1 can further enhance mouse Th17 differentiation, but only in the presence of
TGF- and IL-6 (67, 70, 71). In contrast, IL-1 is the most effective inducer of IL-17
expression in human naive T cells. IL-6 and IL-23 induce a small amount of IL-17
alone and greatly enhance Th17 differentiation in the presence of IL-1 (72, 73).
Furthermore, TGF-, a crucial cytokine for Th17 differentiation in mice, actually
inhibits human Th17 development (72-74). These results suggest that a fundamental
difference exist between mouse and human Th17 biology, which could be a major
obstacle to translating work from animal models into humans.
It has been reported recently in the murine model that S1P has the same potential as
IL-23 in vitro to increase the proliferation and IL-17-secreting activity of T cell
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receptor (TCR)-activated CD4+ T cells grown in the presence of IL-1β, IL-6 and
TGF-β1(75, 76). The differentiation into Th17 cells that is induced by S1P occurs
with corresponding suppression of Th1 and Th2 cytokine production, IFN-γ or IL-4,
respectively (76). Furthermore, the introduction of FTY720 into cultures of Th17 cells
developing under the influence of S1P substantially suppressed the generation of IL-
17 (76). However, most of these effects need to be further substantiated in vivo and in
humans T cells.
1.3.3 Role of SphK in neutrophils
Neutrophils contribute to the elimination of pathogens; however recruitment of
circulating neutrophils to tissue and excessive respiratory burst by activated
neutrophils could be harmful and results in tissue destruction and the development of
the inflammatory process. Neutrophils infiltration is a prominent feature of many
autoimmune lesions such as psoriasis, inflammatory bowel disease (IBD), and
rheumatoid arthritis (RA), although their qualitative and quantitative contribution
therein remains unclear. SphK regulates neutrophil priming to provide essential
defence against infections. Structurally diverse neutrophil-priming agents such as
platelet-activating factor, TNF-α, and the substance P analog, SP-G stimulated a rapid
increase in sphingosine kinase activity in freshly isolated human neutrophils (77).
This activity was blocked by preincubation with the SphK inhibitor DMS. DMS also
inhibited the increase in intracellular Ca2+ concentration stimulated by platelet-
activating factor, fMLP, and SP-G, suggesting that the intracellular Ca2+mobilisation
is dependent on sphingosine kinase activation (77).
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It has been shown that SphK plays key roles in neutrophil activation including
neutrophil chemotaxis (27) and superoxide production (27, 78). Furthermore, it has
also been reported that TNF- and fMLP-stimulated superoxide production in human
blood neutrophils can be regulated by SphK activity, and the superoxide production
can be suppressed by treatment with SphK inhibitor DHS, which is a structural
analogue of sphingosine (78). Recently, it has been reported that in C5a-triggered
responses, such as chemotaxis, degranulation and superoxide generation, primary
human neutrophils are inhibited by DMS (27). These reports demonstrate a key role
for SphK in regulating physiologically relevant events of human neutrophils.
1.3.4 Role of SphK in mast cells
Mast cells are effector cells that, upon activation, release and produce a wide range of
bioactive mediators and cytokines. The action of mast cell activation is not just
limited to allergic responses but it also play an important role in both innate and
acquired immunity to bacterial and parasite infections (79). Increasingly, mast cells
have been demonstrated to be important players in autoimmune diseases such as
Multiple Sclerosis and RA (80). It has been proposed that the differential ratio
sphingosine to S1P, in mast cells, regulates the activity of mast cells (81). In the
mouse mast cells, these two lipids were demonstrated to have opposing effects, with
sphingosine being inhibitory and S1P activating the mitogen-activated protein kinase
(MAPK) pathway, resulting in degranulation and leukotriene release triggered by
FcεR activation (81). Using the antisense approach, we have shown that FcεRI
stimulation leads to SphK1-dependent Ca2+ mobilisation in human mast cells, as well
as SphK1 dependent mast cell degranulation (25). Spiegel’s group, using specific
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siRNA knockdown of the isoforms, found that SphK1 is the critical isoform involved
in IgE/Ag-induced degranulation, migration toward antigen, and CCL2 secretion from
hMCs (mast cells) (82). Furthermore, studies using chemical antagonist of S1P2 or
antisense knockdown of S1P1 or S1P2 have defined specific and non-redundant roles
for each of the receptors in the mast cells (83, 84). In the mouse bone marrow-derived
mast cells, activation of S1P1 is important for cytoskeletal rearrangements and
migration of mast cells toward antigen, but they are dispensable for FcεRI-triggered
degranulation. However, S1P2, whose expression is up-regulated by FcεRI cross-
linking, was required for degranulation and inhibited migration toward antigen (83).
In rat basophilic leukemia cell line RBL-2H3, S1P2 antagonist JTE-013 blocked S1P-
induced mast cell migration (84). Recently Olivera et al. reported that SphK2
regulates mast cell activation whereas SphK1 enhances susceptibility to antigen
challenge in vivo in knockout mice models (85). Put together, these data suggest a key
role for SphK and/or its product S1P on the responses triggered by activated mast
cells.
1.3.5 Role of SphK in monocytes and macrophages
Monocytes and macrophages are important players in inflammation and have been
implicated in several pathologies, such as atherosclerosis (86), in RA (87), and in
cancer (88). SphK activity has been shown to be activated in macrophages through a
wide range of stimuli, and the product, S1P, has been reported to advance wound-
healing processes, in which macrophages are essential, in vitro and in vivo (89). S1P1
and S1P2 have been shown to be expressed by different populations or genetic origins
of macrophages and monocytes (90-92). It has been speculated that changes in the
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concentration of S1P in the circulation or the local environment could induce a switch
from pro-inflammatory M1 to anti-inflammatory M2 macrophage subtypes, thereby
affecting the course of diseases. In a murine model of atherosclerosis, administration
of FTY720 exhibited antiatherogenic potential by augmenting peritoneal macrophages
from M1 to M2 type (93).
It has been shown that activation of monocytes via the high-affinity IgG receptor
(FcγRI) triggers SphK1 activity which is essential for the Ca2+ mobilisation from
internal stores and for mediating the vesicular trafficking of internalized immune
complexes for degradation (24). Ca2+ release is a key event in immune-receptor
signalling, and the fact that it can be regulated by SphK1 activity suggests that SphK1
may regulate a variety of responses triggered by these receptors on monocytes and
macrophages. In addition, the anaphylatoxin C5a utilises SphK1 in order to trigger
several physiologically relevant events, on human macrophages, such as Ca2+ release
from internal stores, chemotaxis, degranulation, and cytokine production (28). More
recently, it has been demonstrated that TNF- rapidly triggers SphK activation and
S1P generation in primary human monocytes. Moreover, by using antisense
knockdown of SphKs, SphK1 is the primary isoform involved in TNF-α triggered
intracellular Ca2+ signals, degranulation, cytokine production, and activation of NF-
κB (29).
1.4 Role of SphK1 versus SphK2 in disease
As described previously, mammalian sphingosine kinase exists in two different
isoforms – SphK1 and SphK2. In addition to having different kinetic properties and
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tissue distribution, the two isoforms were more recently demonstrated to have distinct
roles in immunity. Several in vitro studies have illustrated the importance of SphK1 in
inflammation. Targeting SphK1 isoform with antisense reduces TNF-α - triggered
intracellular Ca2+ signals, degranulation, cytokine production, and activation of NF-
κB, thus suggesting a pivotal role for SphK1 on the pro-inflammatory responses
triggered by TNF-α (29). Knockdown of SphK1 also abolishes the C5a-triggered
intracellular Ca2+ signals, degranulation, cytokine generation, and chemotaxis in
human macrophages and mast cells (25, 28), and, activation of the NADPH oxidase in
neutrophils (27). Furthermore, using siRNA knockdown approach, SphK1 has been
identified as a key player in an in vivo model of C5a-induced acute peritonitis and
systemic inflammation including multi-organ damage (94).
Using knockout mice models, Olivera et al. showed that SphK2 is an intrinsic
regulator of mast cell Ca2+ influx, for activation of protein kinase C, and for cytokine
production and degranulation (85). On the other hand, susceptibility to in vivo
anaphylaxis is determined both by S1P within the mast cell compartment and by
circulating S1P generated by Sphk1 predominantly from a non-mast cell source(s)
(85). In another paper by Spiegel’s group, they studied the roles of SphK1 vs SphK2
in human mast cells using specific siRNA knockdown of the isoforms. In contrast to
the murine model, they found that SphK1 is the critical isoform involved in IgE/Ag-
induced degranulation, migration toward antigen, and CCL2 secretion from human
mast cells (82). However, both isoenzymes were required for efficient TNF-α
secretion (82). Taken together, this suggests that differential formation of S1P by
SphK1 and SphK2 has distinct and important actions in human mast cells.
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SphK1 expression is increased in human IBD colons. Importantly, in a murine model
of IBD, SphK1 deficient mice are protected from disease manifestations such as
weight loss, colon pathology, anemia, and leukocytosis, indicating the therapeutic
potential of SphK1/S1P modulation in the treatment of inflammatory diseases (95). In
contrast, SphK2 is required for the maintenance of T-helper cells homeostasis. CD4+
T cells from SphK2 deficient mice exhibit a hyper-activated phenotype with enhanced
proliferative and Th1 cytokine-secreting capacities, and promote IBD in severe
combined immunodeficiency (SCID) mice (96). This is in part due to IL-2 induced
abnormal accentuated STAT5 phosphorylation and is independent of S1P (96). These
two separate studies conducted using murine models of IBD, together, suggested that
SphK1 is pro-inflammatory, while SphK2 has regulatory function in the disease.
Recently, the divergent roles of sphingosine kinases were demonstrated in kidney
ischemia–reperfusion (IR) injury in the mice. SphK1 but not SphK2 mRNA
expression and activity increased in the kidney following IR injury relative to sham-
operated animals. However, it is the absence of SphK2 that was associated with more
severe kidney damage after IR. This finding suggests that despite minimal changes in
SphK2 expression or activity after IR, constitutive expression of SphK2 is essential
for cell survival pathways after injury. Deficiency in SphK2 also led to increased
neutrophil infiltration into inflamed kidneys, enhanced expression of kidney S1P3,
and increased vascular permeability following IR (97). Together, these observations
could be in part responsible for the increase in injury. In addition, SphK2 is thought to
be important in mediating the kidney-protective effects of FTY720 (97).
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Interestingly, in another study on lipopolysaccharide (LPS)-induced lung injury,
SphK1 knockout mice were much more susceptible to LPS-induced lung injury
compared to their WT counterparts (98). Moreover, over-expression of WT SphK1
delivered by adenoviral vector to the lungs protected SphK1-/- mice from lung injury
and attenuated the severity of the response to LPS, suggesting a protective role for
SphK1 in lung injury (98). On the other hand, over-expression of SphK2 in SphK1-/-
mice exacerbated the injury (98). This suggested that SphK2 activation plays a
distinctly separate role in the regulation of vascular injury, as compared to SphK1
activation.
1.5 Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is a chronic and symmetric polyarthritis with a prevalence
of 1% in the industralised world. It most commonly affects the joints of the hands,
feet, and knees. This autoimmune disease occurs two to three times more frequently
in women, with the peak incidence occurring between the fourth and the sixth decade.
RA is characterised by chronic inflammatory infiltration of the synovial membrane,
which is associated with the destruction of cartilage and underlying bone. In
particular, within inflamed RA synovial membrane, the levels of pro-inflammatory
cytokines (namely TNF-α, IL-1β and IL-6) exceed those of anti-inflammatory agents
(IL-1RA and IL-10) and this likely contributes directly to cartilage and bone erosion
through promoting matrix metalloproteinase (MMP) production and dysregulated
chondrocyte/osteoclast function (99-101).
1.5.1 Etiology of RA
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The etiology of RA is unclear, although the interplay between various genetic factors
and environmental factors has been suggested to contribute to the development of RA.
Genetic factors that contribute to RA susceptibility have been demonstrated in both
studies of twins (102) and multiplex families (103), as well as in genome-wide
linkage scans (104).  The HLA region contributes most to the genetic risks, with the
HLA-DRB1 molecules containing the amino acid sequence
QKRAA/QRRAA/RRRAA at position 70–74 in the third hypervariable region of the
DRB1 chain being associated with both susceptibility to, and severity of RA (105).
On the contrary, HLADRB1 molecules containing the amino acids ‘‘DERAA’’ at the
same position are associated with protection from RA (105). Outside of the HLA
region, chromosome 3q13 region is another susceptibility locus that could account for
up to 16% of the genetic component of RA. Candidate genes in this locus include
those coding for CD80 and CD86, molecules involved in antigen-specific T cell
recognition (104). These studies estimated that genetic factors are responsible for 50-
60% of the risk of developing RA, and the remaining risk may be explained by
environmental factors.
A wide range of environmental factors can contribute to the etiopathogenesis of RA,
including infectious agents, smoking, pregnancy and diet (106). Out of these,
infection was the most studied. Several infectious agents such as human parovirus
B19, Epstein-Barr virus, retroviruses, alphaviruses, hepatitis B virus, Mycobacterium
tuberculosis, Escherichia coli, Proteus mirabilis and Mycoplasma have been reported
as risk factors for RA. The association between RA and infections have been
supported by increased antibody titer or DNA to the infectious organism in RA
patients vs. non-RA patients. However, other epidemiology data oppose these
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associations, and there has been no consistent evidence, so far, that a single infectious
agent or environmental factor is responsible for the development of RA.
Figure 1.2 Effects of cytokines on cell-cell interactions in rheumatoid synovitis
T cells, macrophages, and fibroblasts are all present in the rheumatoid pannus.
Activated T cells can drive synovial macrophages and fibroblasts to produce pro-
inflammatory cytokines such as IL-1 and TNF-α. These further stimulate resident
synovial cells to produce mediators such as collagenase and other neutral proteases,
and result in destruction of cartilage, bone, and penarticular structures. Osteoclasts are
also activated to drive bone resorption.
IL-1, interleukin-1; IFN-γ, interferon γ; GM-CSF, granulocyte-macrophage colony
stimulating factor; TNF, tumour necrosis factor α.
Adapted from Arend, W.P. and Dayer, J.M. 1990. Arthritis Rheum. 33:305-15
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1.5.2 Pathogenesis of Rheumatoid Arthritis: interactions between immune cells and
synoviocytes
The normal synovial lining is one or two cell layers thick, contains both type A
synovial macrophages and type B fibroblast-like synoviocytes (FLS), and is
responsible for maintaining synovial fluid homeostasis. In RA, the thin synovial
membrane is transformed into a proliferating invasive cell mass that eventually
progress to erode the surrounding tissue and bone. The hallmark of RA is the
formation of a tumour-like inflammatory tissue called the pannus. Under the state of
chronic inflammation, the intimal lining of the joint becomes markedly hyperplastic
and assumes features of a transformed, aggressively destructive, granulation tissue
(107). Together with the osteoclasts (108), the pannus invades the subchondral bone
and the cartilage junction zone, leading to joint destruction.
T cells, mainly of the CD4 memory type (109) are activated in the acute phase of the
disease and persist in the synovium throughout the disease course. Activated
synovium T cells are capable of producing various cytokines such as IFN-γ, TNF-α,
IL-15 and IL-17. Through production of cytokines (99) and cell-to-cell contact (110),
they stimulate monocytes, macrophages, and synovial fibroblasts to produce various
cytokines (IL-1, IL-6, TNF-α and IL-15) and matrix metalloproteinases (MMPs), as
well as, activate osteoclasts to drive bone resorption (Fig. 1.2).
Mature plasma cells that secrete autoantibodies (111) are another prominent cellular
component of rheumatoid synovium. The classical autoantibody associated with RA
is the Rheumatoid factor (RF), which is an antibody directed against the Fc portion of
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IgG. However, RF can be detected in other rheumatic diseases, infectious diseases,
and even in 3–5% of apparently healthy individuals. The current diagnostic marker
used in the clinics now is the anti-cyclic citrullinated peptide (CCP) antibody. In
general, the sensitivity of anti-CCP has been comparable to RF (50-75%) with a
higher specificity (90-95%). Furthermore, anti-CCP can be detected years before
onset (112), and it has been shown that anti-CCP correlates with a more erosive
disease (113). In addition to the classical role of autoantibodies production, it is now
clear that B cells play a pivotal role in activation of synovial T cells in the synovial
tissue. In a study using SCID mice, Takemura et al. took synovial tissues from RA
patients, depleted them of B cells using anti-CD20 antibodies, before engrafting them
into the mice. They found that synovial tissue depleted of B cells fail to stimulate
cytokine production from autologous T cells (114). B cells also play a central role in
the histological architecture of synovial lesions. The joints of some RA patients
exhibit structures made up of immune cell aggregates, alike to germinal centers found
in lymphoid organs. B cells have been shown to supply lymphotoxin-b, a key factor in
ectopic lymphoid neogenesis, thus aiding to shape the synovial microenvironment
(115). The importance of B cells in RA is supported by the moderate success of
targeting CD20+ B cells with the chimeric monoclonal anti-CD20 antibody, rituximab
(116, 117).
Unlike the others, neutrophils, in contrast, are found almost exclusively in the
synovial cavity (fluid) and only rarely in the synovial tissue. Their migration through
the synovial interstitium and across the synovial lining into the joint cavity may
reflect lack of expression of specific adhesion molecules for extracellular matrix
constituents. Neutrophils in the synovial fluid are in an activated state, releasing
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oxygen-derived free radicals that are capable of degrading hyaluranic acid, modify
collagen and perhaps proteoglycan structure and/or synthesis, alter and interact with
immunoglobulins, activate proteases and inactivate their inhibitors (118), thus
promoting damage to the joint.
Macrophages are central players in the pathogenesis of RA as they are the main
producers of pro-inflammatory cytokines. Synovial-tissue macrophages are
differentiated from peripheral-blood monocytes. These macrophages express
numerous cell-surface receptors to assist their migration into and retention in the
synovium, and subsequent interactions with other cells and ECM components within
the synovial tissue (119, 120). Activation of synovial macrophages, either by soluble
mediators or direct cell-cell interaction with other cells in the synovium, such as T
lymphocytes (121-125) or synovial fibroblasts in the synovium (126, 127), leads to
the production of a range of pro-inflammatory mediators that promote the
development of chronic inflammation. These include cytokines (IL-1, TNF-α, IL-6,
IL-15, IL-18), chemokines (IL-8, MCP-1, MIP-1α), growth factors (PDGF, VEGF),
proteinases (MMPs) and protease inhibitors (TIMP-1). (reviewed in (128))
Furthermore, macrophages contribute to the bone destruction by enhancing
recruitment of the osteoclast precursors and their differentiation into mature
functional osteoclasts (129).
The high proliferative rate and erosive activity of RA FLS implicate FLS as important
contributors to the chronic RA inflammation. In inflammatory arthritis, the FLS
become hyperplastic (130), and they closely interact with invading immune cells to
form the aggressive pannus tissue that invades and degrades the cartilage and bone.
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Various studies have shown that these FLS are capable of exhibiting pro-
inflammatory characteristics including high proliferative rates, loss of contact
inhibition, constitutive production of pro-inflammatory cytokines, and anchorage-
independent cell growth (131, 132). These observations led to a change in opinions
that FLS are not merely bystanders, but participate actively in the chronic
inflammatory responses of RA. Activated T lymphocytes in the synovium drive FLS
activation via production of soluble mediators or direct cell-cell contact (110, 133).
Like the synovial macrophages, these activated FLS then become potent producers of
various effector molecules that act on a variety of cells (lymphocytes, monocytes,
mesenchymal cells) to modulate joint inflammation and promote matrix degradation
(reviewed in (134)).
1.5.3 Role of Cytokines in RA pathogenesis
A large number of cytokines are active in the joints of RA patients, including TNF-α,
IL-1β, IL-6, IL-15 and IL-17, and it is now clear that these cytokines play an essential
role in the pathogenesis of RA. Therefore, it is not surprising that these cytokines
have become popular targets for therapeutic intervention. The traditional treatment of
RA has been the disease-modifying antirheumatic drugs (DMARDs), with
methotrexate being the most widely used DMARD for RA (135-137). However, this
drug is associated with significant toxicity and it is not clinically beneficial for all RA
patients. With a better understanding of the effector pathways driving in the disease,
biologic therapeutics, such as those targeting the cytokines, have revoluntionised
treatment. The successful targeting of TNF-α using antibodies such as infliximab,
etanercept and adalimumab, is one such example.
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1.5.3.1 TNF-α
TNF-α was first discovered to play a key role in RA after in vitro studies showing that
it has the capability to stimulate collagenase and PGE2 production (138), stimulate
osteoclastic bone resorption and inhibit bone collagen formation (139). Later on, it
was shown that in dissociated RA synovial mononuclear cell cultures, TNF-α and
other cytokines including IL-1 and IL-6, were spontaneously produced over a 5-day
culture period (140, 141). More importantly, IL-1 production was markedly reduced if
TNF-α bioactivity was blocked in these cultures (140). This suggested that a hierarchy
of cytokine network is present in RA, with TNF-α potentially playing a central
modulating role. Using immunohistochemistry, TNF-α and TNF receptors were found
to be expressed in human rheumatoid arthritic synovial tissue (142, 143).
Furthermore, transgenic mice overexpressing human TNFA gene spontaneously
developed peripheral arthritis (144), providing rationale for therapeutics targeting
TNF-α. However, TNF-α antagonists are not without their limitations. Anti-TNF-α
treatment has been associated with adverse side effects including infections,
malignancies and allergies and there remains a subgroup of RA patients that are
unresponsive to the treatment. Unresponsiveness might be intimately linked to
processes that are related to anti-drug development, for example, formation of anti-
anti-TNF antibodies.
1.5.3.2 IL-1β
IL-1 and the IL-1 superfamily members, IL-18 and IL-33, have been implicated in the
pathogenesis of RA as well. However, unlike TNF-α, these have not yet provided
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powerful therapeutics. IL-1α, IL-1β and the natural IL-1 receptor antagonist, IL-1RA,
are expressed in abundance in the synovium (145). IL-1 induces the production of
cytokines such as TNF-α, IL-1 and IL-6 by synovial mononuclear cells, induces the
expression of MMPs by fibroblasts, and stimulates osteoclastogenesis which drives
bone erosion (145-148). In the animal models of collagen-induced arthritis (CIA), it
was demonstrated that anti-IL-1 treatment significantly ameliorated cartilage and joint
destruction via suppression of MMP activity (149). Prophylactic anti-IL-1 treatment
could prevent the onset of the disease completely (150). Furthermore, IL-1RA
deficient mice spontaneously developed chronic inflammatory polyarthropathy with
marked synovial and periarticular inflammation and articular erosion caused by
invasion of granulation tissues closely resembling that of rheumatoid arthritis in
humans (151). As increased expression of IL-1 and decreased production of IL-1RA
has been detected in the RA synovium (152), it has been proposed that a disturbed IL-
1/IL-1RA balance in the synovial plays a role in driving the chronic inflammation in
the synovium. Despite these data suggesting that IL-1 blockade would be beneficial in
RA, clinical results with IL-1 inhibitor have been disappointing. Although Anakinra
(a recombinant, nonglycosylated version of human IL-1RA) reduces inflammation
and slows joint damage, it does so to a much lesser extent than TNF-α inhibitors
(153).
1.5.3.3 IL-6
IL-6 was originally described in 1982 as a B cell differentiation marker (154, 155)
and is now recognised to mediate a range of physiological functions including
maturation and activation of B and T cells, macrophages, osteoclasts and
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chondrocytes (156). Clinical trials results have demonstrated that tocilizumab, a
humanized monoclonal antibody (mAb) specific for IL-6R, can suppress disease
activity and erosive progression in RA patients that are resistant to traditional
DMARDS (157). Moreover, this drug has also been shown to be effective in patients
unresponsive to anti-TNF-α treatment. Tocilizumab is currently at phase III clinical
trials to determine long term safety and efficacy.
1.5.3.4 IL-17
More recently, a third Th-cell subset, known as Th17, was identified (62, 63). The
signature cytokine of Th17 cells, IL-17, has been proposed to be vital in the
pathogenesis of RA. Until recently, IFN-γ was thought to be pathogenic in RA and
CIA. However, several studies have reported that mice deficient in functional IFN-γ
receptor develops a more severe arthritis with earlier clinical onset compared to WT
counterparts (158, 159), and suggested that endogenous IFN-γ counteracts
development of CIA by up-regulating IL-4 production and/or down-regulating IL-2
production (159). Moreover, IFN-γ deficiency renders resistant mice strains such as
C57BL/6 susceptible to CIA (160-162). With the discovery that the IL-12 p40 subunit
is shared by IL-23, it became clearer that in certain animal models of arthritis, the IL-
23/IL-17 signalling pathway might play the main pathogenic role (161). The
incidence of CIA was markedly suppressed in IL-17 deficient mice, and a crucial role
for IL-17 was suggested in activating collagen-specific T and B cells during CIA
(163). Treatment with neutralising antibodies to IL-17 or IL-17 receptor IgG1 Fc
fusion protein after the onset of CIA reduces joint inflammation and prevents cartilage
and bone destruction (164, 165). IL-17 is also required for the development of
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spontaneous arthritis in other mouse models of RA, such as IL-1RA-deficient mice
and SKG mice- BALB/c mice with a mutation of the ZAP-70 gene (166, 167).
Elevated levels of IL-17 were also detected in sera and synovial fluid of patients with
RA and IL-17 -producing cells were found to be present in the T-cell rich areas of the
synovium (168-170). Furthermore, IL-17 induces production of various pro-
inflammatory cytokines and chemokines, MMPs (171). IL-17 can also synergize with
TNF-α and IL-1β in mediating inflammation and joint damage. It has been shown that
combination blockade of TNF-α, IL-1 and IL-17 is more effective in suppressing
arthritis in an ex vivo model of synovial inflammation and bone destruction than
neutralisation of TNF alone (172). More recently, IL-17 was shown to be chemotactic
for monocytes at the concentrations detected in the RA synovial fluid mediated
through p38 mitogen activated protein kinase (MAPK) signalling. Furthermore,
neutralisation of IL-17 in RA synovial fluid or its receptors on monocytes
significantly reduced monocyte migration mediated by RA synovial fluid (173).
These results suggest that treatments designed to block IL-17 may be beneficial in
combination with treatments that block TNF and/or IL-1. IL-17-neutralising therapies
may also be particularly useful for the considerable number of patients who do not
respond to TNF blockade.
1.5.4 Cell contact in RA
T cell cytokines such as IL-4, IL-10, IL-13, and TGF-β have predominantly anti-
inflammatory effects and, in the human system, IFN- alone is a weak inducer of IL-
1β and TNF-α production, suggesting that soluble factors produced by T cells are not
enough to sustain chronic inflammation (174). Therefore, T cells might exert a
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pathological effect through direct cellular contact with monocyte-macrophages (Fig.
1.3). Indeed, studies pioneered by Dayer and colleagues, as well as work from several
other labs have demonstrated that direct contact with stimulated T lymphocytes was a
strong stimulus of human monocytic cells and monocytes. The importance of cellular
contact was first confirmed by experiments showing that in the absence of cytokines,
IL-1 could be induced via T cell-macrophage contact with both Th1 and Th2 cells in
the mice. They also observed that direct contact with stimulated T cells can stimulate
TNF-α production in macrophages in the absence of IFN-γ. Furthermore, plasma
membranes isolated from different stimulated T-cell clones were able to activate
macrophages, establishing that direct contact with stimulated T cells was a potent
mechanism inducing macrophage effector functions (175). Subsequently, it has been
demonstrated by Dayer and other labs that contact-mediated activation of human
monocytes/macrophages is a potent pro-inflammatory mechanism that triggers
massive upregulation of cytokines such as TNF-α, IL1-ß, IL-6 (176-179), as well as,
metalloproteinases (180).
In chronic inflammatory diseases such as RA, the synovium is very cellular and
several different cell types, including T lymphocytes and macrophages lie in close
proximity of one another, allowing for reciprocal cellular crosstalk (Fig. 1.3). Studies
have shown that TNF-α production in the synovium is dependent on the presence of
CD3+ T cells as removal of CD3+ T cells resulted in significant reduction of TNF-α
production from synovial mononuclear cells (181). Moreover, if the physical contact
between the two cell-types is blocked, TNF-α production is also blocked.
Furthermore, McInnes et al. demonstrated that freshly isolated, paraformyldehyde-
fixed T lymphocytes from the synovial fluid might induce TNF-α production directly
by blood or synovial macrophages via direct cell-to-cell contact without additional
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exogenous stimulation. This effect is further enhanced when the T cells are activated
with cytokines such as IL-15 (122). In another study done by Brennan et al., cytokine-
stimulated T-cells (25 ng/ml TNF-α, 100 ng/ml IL-6, and 25 ng/ml IL-2 for 8 days in
culture) or T cells isolated from RA synovial tissue displayed the ability to induced
TNF-a production in normal blood monocytes via the NF-κB pathways (181) .
It has been proposed that “bystander” activation of the T-cells by a cocktail of
cytokines present in the inflamed synovium confers on the synovial T cells the ability
to activate macrophages (122, 123, 182). Although the precise ligands involved in the
cell-cell interaction is still unclear, there have been studies implicating molecules such
as LFA-1 (lymphocyte function associated antigen-1) (183), CD69 (121), CD40
(125), and membrane-bound cytokines e.g. TNF-α (184). Similarly, activated T cells
have also been shown to be able to interact with and activate synovial fibroblasts via
direct cell-cell contact (110, 133, 185). Membrane-bound cytokines, including TNF-α
and IL-1β, but not CD69, CD154 or CD11b, seem crucial to such interactions
between T cells and FLS to induce production of MMP and prostaglandin by synovial
fibroblast (185). Furthermore, the synovial cells have been suggested to interact with
each other via ligation of CD97 on the macrophages and CD55 on the fibroblasts
(127). In vitro studies have also demonstrated that direct interaction between
monocytes and RA FLS promote production of IL6, IL-8 and GM-CSF in the
synovium (126). Direct cell-cell contact with stimulated T lymphocytes is one of the
principal pathways triggering activation of monocytes/macrophages in the absence of
infectious agents (186), promoting persistent excessive secretion of pro-inflammatory
mediators. Therefore, it has been proposed to be an important mechanism involved in
the pathogenesis of chronic inflammatory diseases such as RA.
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Figure 1.3 Pathways by which T cell interactions can contribute to synovial
inflammation
T cells activated by cytokine combinations, by contact between extracellular matrix
and endothelium and potentially by autoantigen, can activate the production of
cytokines, MMPs and prostaglandins (PGs) by macrophages and FLS, creating
potential positive feedback loops, and leading in turn to articular damage. Contact
interactions might be variably mediated through adhesion molecules or membrane
cytokines. The parallel secretion of pro-inflammatory and anti-inflammatory
cytokines and cytokine receptors further modulate responses.
Adapted from McInnes, I.B., B.P. Leung, and F.Y. Liew. 2000. Arthritis Res. 2:374-8.
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1.6 Asthma
Asthma is one of the most common disorders encountered in clinical medicine in both
children and adults. The incidence, morbidity, and mortality of this disease have been
increasing at an alarming rate in industrialised countries around the world over the
last few decades. Asthma manifests as recurrent episodes of wheezing, breathlessness,
chest tightness, and coughing (187). The causes of asthma are believed to be
multifactorial, including genetic factors and environmental stimuli. Asthma
susceptibility genes fall into four main groups: genes associated with innate immunity
and immunoregulation (e.g. CD14 (188)); genes associated with T helper 2 (Th2)-cell
differentiation and effector functions (e.g. GATA3 (189), IL4 (190, 191), IL13 (192));
genes associated with epithelial biology and mucosal immunity (e.g. SPINK5 (193));
and genes associated with lung function, airway remodelling and disease severity
(ADRB2 (194)). A variety of environmental stimuli has been linked to asthma, such as
allergens (i.e. molds, house dust mites, and plant and animal debris), diet (obesity),
infectious stimuli (particularly viruses), and airborne pollutants (ozone and diesel) and
irritants (tobacco smoke) (reviewed in (195-198). It is important to recognise that
asthma is a complex disease, and its incidence is determined by intricate interactions
between genetic and environmental factors.
1.6.1 Asthma Pathogenesis
Atopic asthma is characterised by airway hyperresponsiveness (AHR), inflammatory
infiltrates in the bronchial walls containing eosinophils, and elevated serum IgE
levels. Asthma pathogenesis can be broadly categorized into the acute phase and the
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chronic phase (Fig. 1.4). Different immune cells dictate the different phases of the
disease. It is widely accepted that mast cells and IgE are the main players during the
acute phase. Mast cells are thought to be the main link between IgE and AHR. Mast
cells express approximately 300 000 high affinity IgE receptors/cell, but aggregation
of only 100 receptors is required for detectable responses. Crosslinking of IgE-bound
FcεRI on the mast cells by allergens triggers the release of inflammatory mediators
such as histamine, the synthesis of prostaglandins and leukotrienes, and the
transcription of cytokines (199). In addition to mediator release, mast cells are also
being recognised for their ability, by direct cell-to-cell contact, to alter airway smooth
muscle (ASM) cells, mucus production and T cell activation, leading to AHR and
eventually elicit an inflammatory infiltrate (200). Mast cell derived mediators such
histamine, LTD4, PGD2, and tryptase have been found in bronchoalveolar lavage
(BAL) from patients with allergic asthma (201, 202), supporting the role of these cells
in the early allergic reaction in asthma.
The consensus is that chronic phase of asthma is orchestrated by CD4+ Th2 cells and
their cytokines. Th2 cytokines such as IL-4, IL-5, IL-9 and IL-13 play a critical role in
promoting airway inflammation and are required for the development of airway
eosinophilia and IgE production (203-205). Lung biopsies of asthmatic patients have
revealed pulmonary infiltration of lymphocytes, particularly of the Th2 type,
macrophages and mast cells. These cells, together with the resident airway cells,
interact with one another to initiate and perpetuate allergic airway inflammation
(206). IL-4, IL-5, and IL-13 have been found to be elevated in BAL samples of
patients with asthma or asymptomatic disease (207, 208). The ability of Th2 cells to
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induce the characteristic features of asthma was recently shown in murine models. In
a study by Cohn et al., airway eosinophilia, and mucus hypersecretion were observed
in mice receiving Th2 cells transfer after 7-10 days of challenge with inhaled 1%
OVA in PBS (209). In a later study, the group demonstrated, as well, that mice
receiving Th2 cells exhibited AHR while mice receiving Th1 cells did not (210).
These studies suggested that the activation of Th2 cells is sufficient for the induction
of inflammation and the chronic pathological changes associated with asthma.
ASM cells function as the primary effector cells that modulate bronchomotor tone.
However, beyond its contractile functions, ASM also contributes to the pathogenesis
of asthma in various ways. Airway instillation of bacterial LPS into rat lungs
enhanced intercellular adhesion molecule 1 (ICAM-1) expression in the ASM (211).
Lazaar et al. demonstrated the constitutive expression of CD44 on human ASM cells
in culture as well as in human bronchial tissue transplanted into SCID mice. Levels of
ICAM-1 and VCAM-1 expression are also induced on ASM by inflammatory
mediators such as TNF-α (212). Although the function of CAMs on ASM remains
incompletely defined, surface expression of CAMs may play a role in cell-cell
interaction with other inflammatory cells, such as T-cells (212), eosinophils (213) and
mast cells (214). Under the influence of inflammatory cytokines such as IL-6, ASM
may be induced to undergo hyperplasia and hypertrophy (215) and contribute
ultimately to airway obstruction. ASM can also secrete various inflammatory
mediators such as GM-CSF and IL-5 which contribute to the proliferation and
survival of eosinophils (216, 217). ASM also plays prominent role in the recruitment
of inflammatory cells as it has also been demonstrated to be a source of various
chemokines such as eotaxin (218), MCP-1 (219) and RANTES (220).
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Figure 1.4 Overview of asthma pathogenesis
The interaction of allergen with specific IgE passively absorbed to mast cells leads to
the noncytolytic, energy-dependent release of histamine and lipid mediators from
mast cells. This might account for the acute airway narrowing (bronchospasm) that
occurs within minutes of exposure to specific allergen. Antigen-presenting cells in the
airways, particularly DCs, process and present allergenic peptides to CD4 cells in an
MHC class II restriction fashion. Th2 CD4 cells elaborate IL-4 and IL-13, which are
involved in IgE production by B cells; TGF-β, together with IL-4 and IL-13, have
direct effects on fibroblasts, epithelial cells, and airway smooth muscle, which in turn
leads to the release of growth factors and fibrogenic factors involved in remodelling,
AHR, and airway narrowing. IL-5 derived from Th2 cells and other cells facilitates
the development and activation of eosinophils. Eosinophils have a direct effect on
airway narrowing through the release of basic proteins and lipid mediators and
indirectly influence airway remodelling through the release of TGF-β, IL-4, and IL-
13. These cytokines are also elaborated from mast cells, and this mechanism might
also amplify the chronic asthma process.
LT, Leukotriene; Epi, epithelial cells; fib, fibroblasts; ASM, airway smooth muscle;
APC, antigen-presenting cell; TGF, transforming growth factor.




IL-4 is a classical Th2 cytokine, important for Th2 cell differentiation (221, 222) and
immunoglobulin isotype switch from IgM to IgE (223). Several lines of in vivo
evidence support the importance of IL-4 in Th2 priming in allergic responses. For
instance, treatment of mice with anti-IL4 antibodies during both the sensitisation and
challenge phases protected the mice from allergen-induced AHR, while treatment
during the allergen challenge stage alone did not confer protection (224). IL-4
transgenic mice have increased IgE values and allergic-like disease with ocular
lesions infiltrated with mast cells and eosinophils, highlighting its role in IgE
production (225). On the other hand, mice deficient for IL-4 displayed attenuated
airway eosinophilia, although different effects on AHR were observed in different
models, possibly due to the genetic background differences of the mice (226, 227).
Furthermore, IL-4 can induce the expression of VCAM-1 on endothelial cells,
producing enhanced adhesiveness of the endothelium for T cells, eosinophils,
basophils, and monocytes, which is characteristic of allergic reactions (228).
1.6.1.2 IL-13
IL-13 shares a receptor complex with IL-4 which includes the IL-4 receptor α (IL-
4Rα) chain and an IL-13-binding chain designated as IL-13Rα1 (229, 230). Therefore,
it is not surprising that IL-13 share many similar effects with IL-4 (231, 232). In a
transgenic mouse model, overexpression of IL-13 in the lungs induces inflammation,
mucus hypersecretion, subepithelial fibrosis and eotaxin production, supporting the
hypothesis that IL-13 is an important mediator of allergic asthma (233). Moreover,
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overexpression of IL-13 in the airway epithelium was sufficient to induce AHR and
mucus production (234). Neutralisation of IL-13 by intratracheal administration of
soluble IL-13 receptor (IL-13R) reduced AHR and mucus production, demonstrating
a direct role of IL-13 in allergic airway inflammation (232, 235).
1.6.1.3 IL-5
Airway eosinophilia is a hallmark of allergic asthma. IL-5 is essential in regulating
eosinophil responses such as proliferation, survival and activation, and is thus crucial
in orchestrating eosinophilic inflammation of asthma (236). IL-5 is found to be
elevated in BAL from human asthmatics and allergic mice (208, 237). IL-5 deficient
mice have a marked reduction in eosinophil number in the airway, lung tissue and
peripheral blood in allergic asthma inflammation (238).  In line with these
observations, in a murine model of OVA-induced asthma, treatment with anti-IL-5
antibody did not affect B cell (Ig serum levels), T cell (cytokine production), or mast
cell function (immediate cutaneous reactivity) but completely inhibited development
of eosinophilic lung inflammation and AHR (239). On the contrary, other studies
showed that although anti -IL-5 is efficient in attenuating eosinophilia, it has no
profound effect on AHR in the mice (227). Thus, airway eosinophilia might not be a
requirement for allergen induced AHR (240) (241).
1.6.1.4 Eotaxin
Eotaxin, a C-C chemokine, is highly expressed in asthmatic airway epithelium and is
pivotal for the recruitment of eosinphils (242-244). Thus, it has been proposed that
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airway eosinophilia together with various inflammatory cytokines as described above
may contribute to eventual AHR in asthma.
1.6.1.5 IL-17
The decades-old Th1-Th2 paradigm has been challenged recently, and a distinct
subset of Th cells emerged, known as the Th17 cells. The Th17 subset of T cells is
characterised by the secretion of IL-17, now known as IL-17A. Transcription factor
RORγt and STAT3 are essential for the development of Th17 cells (245, 246). Studies
have shown that the key to Th17 differentiation in the mouse is the combination of
transforming growth factor-β (TGF-β) and IL-6 (65-67), and expands up to full
potential in the presence of IL-23 (68, 69). In addition, TNF-α and IL-1β can further
enhance mouse Th17 differentiation, but only in the presence of TGF-β and IL-6 (67,
70, 71). In contrast, IL-1β is the most effective inducer of IL-17 expression in human
naive T cells. More recently, IL-17A has been found to be overexpressed in airways
of asthmatic patients and is associated with neutrophil influx (247). In addition, IL-
17A has been shown to have the ability to induce IL-8 and eotaxin-1 (CCL11)
production by human ASM cells via the MAPK pathways (248, 249). In the mouse
model of allergic asthma, IL-17A has been shown to play a pathogenic role in the
sensitisation phase but is a negative regulator of established allergic asthma (250). In
addition, another group demonstrated that inhalation of nebulized ovalbumin (OVA)
by sensitised mice with bronchial eosinophilic inflammation induced early IL-17
mRNA expression in inflamed lung tissue, associated with a prominent bronchial
neutrophilic influx. Anti-IL-17 monoclonal antibodies (mAb) injected before allergen
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inhalation or repeatedly during the inhalatory challenge phase strongly reduced
bronchial neutrophilic influx but enhanced eosinophil influx into the airways (251).
1.6.2 Asthma therapy
Currently, the gold standard for asthma therapy is inhaled corticosteroids. Although
inhaled corticosteroids are effective, compliance with this medication is surprisingly
poor. Even when taken regularly, inhaled corticosteroids do not notably modify the
course of the disease and are not curative because asthma symptoms and
inflammation rapidly recur when the treatment is discontinued. Moreover,
administration of corticosteroids is associated with adverse effects such as alterations
in bone metabolism when taken over the long term. Also, there exists a subset of
patients with difficult asthma (approximately 5%), especially in cigarette smokers,
who respond poorly to conventional asthma treatments. Consequently, there is an
increased need for the development of new agents for the treatment of asthma, and
some of the more popular targets include the Th2 cytokines, transcription factor NF-
κB (252), and p38 MAP kinase (253).
1.6.2.1 IL-4 and IL-13 therapy
Although in the initial clinical studies, soluble humanized IL-4 receptor (sIL-4r)
administered by the nebulizer appears to be effective in controlling asthma in patients
who discontinued inhaled steroids (254, 255), subsequent studies in patients with mild
asthma prove to be disappointing, and this treatment has been now withdrawn. The
more recent and efficient approach is to use a mutated form of IL-4 (BAY 36-1677)
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that binds to and blocks the IL-4 receptor and IL-13 receptor α1, thereby blocking
both IL-4 and IL-13 actions (256).The shortfall of this treatment, however, is its short
duration of action.
1.6.2.2 IL-5 therapy
The results of the clinical studies with neutralising IL-5 antibodies were
disappointing. Humanized monoclonal antibodies to IL-5 have been developed and a
single intravenous administration of these antibodies (mepolizumab;
GlaxoSmithKline) can markedly reduce blood eosinophils for more than 3 months
and prevents eosinophil recruitment to the airways after allergen challenge in patients
with mild asthma (257). However, this treatment has no significant effect on baseline
AHR, which suggests that eosinophils might not be essential for these responses in
humans. Indeed, in a clinical study of mepolizumab in patients with moderate to
severe asthma that was not controlled by inhaled corticosteroids, a reduction in
circulating eosinophils was observed in patients receiving the treatment. However, no
significant improvement in either asthma symptoms or lung function was
demonstrated (258). It was noted that although mepolizumab reduces circulating
eosinophils by more than 95%, it reduces airway eosinophils only by 55%, which
might explain its lack of clinical efficacy (259). Nevertheless, it is important to note
that the study population typically consists of a group of patients with very difficult
asthma, who are already taking and failing conventional corticosteroids treatment.
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1.7 Rationale: The expanding view of S1P/SphKs and their functions in
inflammation
The regulation of sphingolipids, in particular the roles of SphKs and their product,
S1P, are becoming a topic of intense research in immunology. Regulating SphK
activity and maintaining S1P homeostasis are important for preventing unwanted
immune responses and for maintaining appropriate vascular barrier integrity (51),
disruption of which increases permeability to fluid and solute and is the main
pathophysiological mechanism of many inflammatory disease processes, such as
sepsis, where S1P has been demonstrated to be beneficial (260). In plasma, S1P
concentration is in the micromolar range (46), and can be found in association with
the high-density lipoproteins (261). S1P is stored in relatively high concentrations in
human platelets, and it is released into the blood stream upon platelet activation (89).
Thus, S1P may also have a critical role in platelet aggregation and thrombosis and
could aggravate cardiovascular ailment. Indeed, S1P levels were found to be
abnormally high in patients with coronary artery disease, and were found to be a
better predictive factor for disease than traditional assessments that include various
forms of exercise stress testing (262). S1P levels are also increased in the BAL fluids
from allergen-challenged asthmatics and in the joints of patients with rheumatoid
arthritis (263, 264). So, understanding the mechanisms that are involved in the
modulation of S1P levels during physiological and pathophysiological states might
provide some ideas on how one can manipulate S1P level to influence immunity.
Of significant interest is the promising preclinical activity of a structural analog of
S1P, FTY720. Recent studies suggesting that the prototype drug FTY720, a
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sphingosine analogue, acts as an immunosuppressive agent highly effective in
prolonging allograft survival (265) as well as autoimmune diseases in several animal
models, such as, non-obese diabetic mouse model of autoimmune type 1 diabetes
mellitus (266, 267), autoimmune myocarditis (268), myasthenia gravis (269) and
systemic lupus erythematous (SLE) (270), and adjuvant- and collagen-induced
arthritis in rats (271). Currently, this drug is being tested in human trials for its
therapeutic uses in multiple sclerosis (272). It is now known that SphK2 is the
primary enzyme responsible for phosphorylating FTY720 (273). After being
phosphorylated, FTY720 becomes activated, and disrupt lymphocyte trafficking by
decreasing lymphocyte egress from secondary lymphoid organs (274). In spite of the
promising activity of FTY720, there have always been safety concerns regarding the
sequestration of immune cells in the secondary lymphoid organs. Indeed, this drug has
been tested previously in for use in human renal transplantation (275, 276) and the
phase III results proved to be disappointing (265, 266). In the phase III clinical trial,
kidney-transplant recipients receiving 5 mg FTY720 plus reduced dose cyclosporin A
exhibited higher incidence of humoral acute rejection. In addition, serious side effects,
such as decreased renal function, were observed when FTY720 was used in
combination with cyclosporin (reviewed in (277)).
To modulate S1P activity and maintain homeostasis, another possible method is to
target SphK activity. As reviewed in the earlier paragraphs, SphK activity has shown
to be potentially important in various inflammatory responses, as it modulates
immune cell proliferation and differentiation, migration and chemotaxis, cytokine and
chemokine production. Stimulation of various plasma membrane receptors involved
in inflammatory responses, such as the PDGF, FcεRI and FcγRI, fMLP and C5a, as
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well as TNF-α receptors trigger rapid production of S1P through SphK activation.
Moreover, inhibition of SphK activity using pharmacological inhibitors such as DMS,
or oligonucleotides knockdown of the enzyme, strongly reduced cellular events
triggered by these receptors, suggesting a role of SphK in inflammation. Thus,
inhibition of SphK could potentially be used as a novel therapeutic to treat
inflammatory disorders. In this current project, I studied the role of SphK1 and SphK2
in both in vitro and in vivo models where I specifically look at these two isoenzymes





2.1 Preparation of DMS, SKI2, antisense oligonucleotides, and siRNA
N,N-dimethylsphingosine (DMS; Cayman Chemical, Michigan, USA) was prepared
as a 50 mg/ml stock in ethanol and diluted to the appropriate concentration in sterile
PBS or culture media before use. Sphingosine Kinase Inhibitor 2 (SKI2; Cayman
Chemical, Michigan, USA) was prepared as a 10 mg/ml stock in DMSO and diluted
to the appropriate concentration in culture media before use. Both DMS and SKI2
were stored at -20°C. The antisense oligonucleotides were purchased from 1st BASE,
Singapore, with the following sequences: human SphK1, C*C*C GCT GGA TCC
ATA ACC* T*C (Modification: PTO C(1), PTO C(2), PTO C(18), PTO T(19));
Scrambled control, G*G*C TCC TCC TGA CGG TGA* C*G (Modification: PTO
G(1), PTO G(2), PTO A(18), PTO C(19)). All antisense oligonucleotides were diluted
to a stock concentration of 100 µM in sterile 1x TE buffer, pH8, provided by the
manufacturer. The siRNA sense and antisense strands were purchased from Qiagen.
Details of the sequences can be found in table 2.2. RNAse-free suspension buffer
provided by the manufacturer was added to each lysophilized siRNA to obtain 20 µM
stock solution. Each siRNA tube was heated to 90°C for 1 minute, and incubated at
37°C for 30 minutes. All antisense oligonucleotides and siRNA were stored at -20°C.
2.2 Patient and clinical samples
Peripheral blood (PB) was collected from RA patients who fulfilled the American
College of Rheumatology 1987 diagnostic criteria (278), following approval from the
hospital’s institutional review board (Tan Tock Seng Hospital, Singapore) and written
informed consent was obtained from all patients.
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2.3 Cell culture
The human acute T cell leukemia cell lines (Jurkat), human promonocytic lymphoma
cell line (U937) and human promyelocytic leukemia cell line (HL-60) were used. All
cells were maintained in RPMI 1640 (GIBCO® Invitrogen, Singapore) supplemented
with 2 mM L-glutamine (GIBCO® Invitrogen, Singapore) , 100 I.U./ml penicillin and
100 µg/ml streptomycin (PAA Laboratories, Linz, Austria), and 10% heat-inactivated
Fetal calf serum (FCS; Hyclone, Thermo Fisher Scientific Inc., USA ). Supplements
were stored in 5 ml aliquot (x100 final concentration) at -20°C and added to medium
prior to culture.  Murine lymphocyte proliferation medium consisted of complete
RPMI, 25mM HEPES (GIBCO® Invitrogen, Singapore) and 2.5 µg/ml amphotericin
B (GIBCO® Invitrogen, Singapore). FCS was heat inactivated at 56°C for 30 minutes
in a waterbath, hand-shaked every 5 minutes, then stored in 50 ml aliquots at -20°C.
Culture was performed at 37°C in a humidified incubator with 5% CO2. Cells were
counted directly using a Neubauer haemocytometer (Weber Scientific International
Ltd, UK) on a Nikon ECLIPSE E200 microscope. Viability was assessed
microscopically by trypan blue exclusion (0.1% trypan blue (MP Biomedicals, Ohio,
USA), 0.1% acetic acid (BDH Lab, Supplies, Leics, UK), phosphate buffered saline
PBS)
2.3.1 Cell line maintenance
Human cell lines were maintained in complete RPMI with 10% FCS between 2 to 5
x105 cells/ml and subcultured every 2-3 days. For functional assays, cells were
washed twice in PBS before suspension to the desired concentration and addition of
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indicated stimuli. Cells were stored in complete FCS; 10% dimethyl sulfoxide
(DMSO; AppliChem, LLC, Florida, USA) at -80°C or in liquid nitrogen.
2.3.2 Peripheral Blood Mononuclear Cells (PBMC) preparation
Mononuclear cell population was obtained by density gradient centrifugation. After
collection into heparinised sterile universals (10 I.U./ml preservative free heparin),
venous blood was diluted 1:2 in complete RPMI. 3 ml diluted blood was layered over
3 ml of Histopaque®-1077 (Sigma-Aldrich, USA) in a 15 ml conical tube spun at
500g for 30 minutes at 22°C. Mononuclear cells should band at the interface between
the Histopaque®-1077 and the plasma. The mononuclear fraction was collected and
washed thrice in medium before adjustment to the required concentration. This
population was designated PBMC.
T cell enrichment was performed by negative selection using successive adherence
steps to obtain a peripheral blood T cell fraction (PBTL). Mononuclear cell
suspensions obtained above were incubated at 2 x 106 cells/ml in 75 cm2 T75 (Nunc,
Thermo Fisher Scientific, USA) tissue culture flasks for 1 hour, then non-adherent
cells were further incubated overnight in complete RPMI with 10% FCS. Cells
remaining non-adherent were collected and washed thrice in medium before
suspension to desired concentration. Cellular purity was assessed by FACS analysis
using BD FACSCalibur™ Flow Cytometer for CD3, CD14, CD19 marker expression.
PB monocytes were prepared by selecting adherent cells during the T cell enrichment
process as described above. Cells which adhered after 1 hour and 16 hours incubated
steps were removed by a cell scraper and maintained in 10% FCS at 5 x 105 cells/ml
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until required. Prior to use, they were first gently washed in situ to remove non-viable
monocytes or residual non-adherent lymphocytes. Cell purity was assessed by FACS.
2.3.3 Synovial fluid preparation
Synovial fluid was obtained by joint aspiration from RA and osteoarthritis (OA)
patients with written informed consent and stored at –80°C until estimation of S1P by
ELISA (Rheumatology Division, UCLA).
2.3.4 Murine lymph node cell preparation
Draining lymph nodes (popliteal and inguinal) and thoracic lymph nodes from the
lungs were aseptically removed from the mice and gently minced through cell
strainers (BD Biosciences, California, USA) using a 10 ml syringe plunger to prepare
a single-cell suspension. This cell suspension was washed thrice in complete RPMI,
and resuspended to the desired concentrations. Cells were cultured at 2 x 106 cells/ml
in RPMI 1640 medium supplemented with 2 mM L-glutamine, 100 IU/ml penicillin,
100 µg/ml streptomycin, 25 mM HEPES buffer, and 10% heat-inactivated FCS .
2.3.5 Antigen-specific in vitro culture
For the CIA model, draining lymph node cells were stimulated with graded
concentrations of type II collagen (CII; Sigma-Aldrich, USA) (50 µg/ml proved to be
optimal and therefore data for this are shown) or concanavalin A (Con A; Sigma-
Aldrich, USA) (5 µg/ml) for 72 hours unless stated otherwise, and the supernatants
49
from parallel triplicate cultures were stored at -80°C until analysis of cytokine
concentrations by ELISA. For the asthma model, thoracic lymph node cells were
cultured with 200 µg/ml Ovalbumin (OVA; Sigma-Aldrich, USA) or Con A (5 µg/ml)
for 72 hours unless stated otherwise, and the supernatants from parallel triplicate
cultures were stored at -80°C until analysis of cytokine concentrations by ELISA.
After 72 hours, proliferation assays were performed in triplicate in 96-well plates
(Nunc, Thermo Fisher Scientific, USA) as described in section 2.3.9 for another 24
hours and measured by Alamar Blue according to the manufacturer’s
recommendations (Serotec, Oxford, UK). OVA, collagen and Con A were
resuspended to 1 mg/ml in RPMI supplemented with 10% FCS before dilution and
use in culture.
2.3.6 Cell contact protocol
The ability of T lymphocytes to regulate the pro-inflammatory activity of
macrophages by direct cell-to-cell contact can be investigated by fixing T cells after
activation but prior to co-culture with macrophages. Jurkat cells or PBTL were
cultured in 75 cm2 flasks for 72 hours, unless stated otherwise, in complete RPMI in
the presence of medium alone (control) or a combination of 1 µg/ml
phytohaemagglutinin (PHA; Sigma-Aldrich, USA) and 1 nM phorbol 12-myristate
13-acetate (PMA; Sigma-Aldrich, USA). Cells were washed thrice then fixed on ice
for 2 hours in filter sterilised (Millex-GV, Millipore, France) 1% paraformyldehyde
(PFA; Sigma-Aldrich, USA) in PBS. Fixed cells were washed three times and
resuspended to 4 x 106 cells/ml in RPMI, then immediately added in equal volume to
5 x 105 cells/ml of either U937, HL-60, or PB monocytes. Cell contact assays are
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typically done in 96-well format, with a total volume of 200 µl per well. Treatment
includes sphingosine kinase inhibitors DMS (1-10 µM) and SKI2 (5-20 µM), and
antisense oligonucleotides targeting SphK1 (10 µM). After a further 48 hours,
supernatants were harvested and stored at -20°C prior to cytokine measurement by
ELISA.
Identical cultures as described above were established in which the T cells were
separated from U937 cells  by a culture-well insert (BD Falcon™, California, USA)
with a porous membrane (pore size: 0.45 µm), which prevented cell-contact but
allowed soluble factor mediated communication. Supernatants were harvested after a
further of 48 hours and cytokine measurement by ELISA.
2.3.7 Treatment protocol
Desired concentration of DMS or SKI2 were added to the U937, HL60, or PB
monocytes 30 minutes prior to addition of fixed T cells to give a total volume of 200
µl per well. The cultures were incubated for 48 hours before supernatants were
harvested and stored at -20°C until further analysis with ELISA. Antisense
oligonucleotides were added to the HL-60 cell cultures 48 hours prior to cell contact
experiment. Antisense transfection was done using Lipofectamine RNAiMAX
(GIBCO® Invitrogen, Singapore) according to the manufacturer’s recommendations.
Briefly, HL-60 cells (2 x 106 cells/transfection) were transfected with a final
concentration of 10 µM antisense. For control experiments, transfection was
performed without antisense or with scrambled control antisense (10 µM). After 48
hours of culturing, transfected cells were checked for viability by Alamar blue and
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diluted to a concentration of 5 x 105 cells/ml. Jurkat T cells were stimulated for 48
hours with PHA/PMA in complete RPMI, then fixed in 1% paraformaldehyde.
Control non-activated Jurkat cells were also fixed for comparative purposes. Fixed
Jurkat T cells were co-cultured with the transfected HL-60 cells as described above.
Supernatants were harvested after 48 hours of co-culture for cytokine estimation by
ELISA.
2.3.8 Degranulation Assay
Degranulation was assessed by measuring the release of β-hexosaminidase from U937
cells in medium and cell lysates by a colorimetric assay as described (25). U937 cells
(2 x 105/sample) were stimulated by the addition of fixed Jurkat cells in the presence
or absence of DMS for 1 hour. Following stimulation, 50 µl of the sample supernatant
was incubated with 200 µl of the enzyme substrate, 1 mM p-nitrophenyl-N-acetyl-D-
glucosaminide (Sigma-Aldrich, Singapore) in 0.1 M sodium citrate buffer (pH 4.5),
for 1 hour at 37°C. The remaining cells were lysed with 1% Triton X-100 for 30
minutes to get the total β-hexosaminidase concentration. A 50 µl aliquot of the lysed
cells was removed and analysed as described above. The product p-nitrophenol, was
converted to the chromophore, p-nitrophenate, by the addition of 0.1 M sodium
carbonate buffer. Absorbance was read at 400 nm using ASYS UVM 340 microplate
reader (ASYS Group Asia Pte Ltd, Singapore). Results were reported as the
percentage of intracellular β-hexosaminidase that was released into the medium after
correction for spontaneous release.
2.3.9 Proliferation Assay
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Proliferation assays were typically performed in triplicate after 48 hours of cell-
contact experiment or 72 hours of antigen-specific in vitro culture unless stated
otherwise. 100 µl of supernatant from each well were aliquoted into a new 96-well
plate and stored at -20°C for further analysis with ELISA. Care was taken not to
disturb the cells at the bottom of the wells. Alamar blue reagent (Serotec, Oxford, UK)
was prepared by adding 10 µl of the reagent into the remaining 100 µl of cells in each
well. The plate was then incubated at 37°C in a humidified incubator with 5% CO2 for
6 to 24 hours. Absorbance is monitored at 570nm and 600nm using ASYS UVM 340
microplate reader. Percentage viability is plotted as follow:
% viability with respect to U937 cells alone = (Ab570- Ab600)/ (Ab570-Ab600)U937 X
100%. Absolute cell number was determined by an established standard curve in
parallel culture.
2.4 Animal model of inflammation
2.4.1 Induction of collagen induced arthritis (CIA) in mice
Collagen Induced Arthritis (CIA) is a widely used experimental model of polyarthritis.
It can be induced in susceptible strains of mice which express the H-2q haplotype by
immunisation with type II collagen and has histopathologic features common with
rheumatoid arthritis (279). Male DBA/1 mice at 8-10 wk old were obtained from the
Laboratory Animals Centre, National University of Singapore (NUS). Animals were
housed in the Animal Holding Unit, NUS, and all experiments were conducted
according to the Institutional Guidelines for Animal Care and Use Committee, NUS.
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Mice were quarantined for 7-10 days before the study commenced. Bovine type II
collagen (CII; Sigma-Aldrich, USA) was solubilised at 4 mg/ml in 0.01M acetic acid
at 4°C overnight. The next day, collagen was emulsified in an equal volume of freshly
prepared Freund’s complete adjuvant (Difco, Detroit, MI) supplemented with 4 mg/ml
of heat killed Mycobacterium tuberculosis, H37RA (Difco). Male DBA/1 mice were
immunised intradermally by two injections at the base of the tail with a total of 100 µl
of emulsion (CII; 200 µg) on day 0. The animals were boosted again with collagen
(200 µg in PBS) was given again on day 21 by intraperitoneal (i.p.) injection. A
gradual onset of arthritis was observed 7 – 10 days after the i.p. booster and animals
were observed for up to 8 weeks for the development of arthritis.
2.4.2 CIA model: Treatment protocols
To investigate the effect of SphK modulation in murine CIA, DBA/1 mice (22-25 g)
received daily i.p. injections of DMS diluted in PBS at the doses of 200 or 400
µg/kg/mouse (n = 16 mice/group) from days 21-23 and then once every 2 days until
day 45. The doses of DMS chosen are consistent with previous in vivo murine studies
(15, 28). Control mice received PBS supplemented with ethanol as carrier control (n =
15 mice/group). To investigate the role of SphK1, and SphK2 in murine CIA, siRNA
sense and antisense strands were purchased from Qiagen. Sequence details can be
found in table 2.2. For both SphK1 and SphK2 groups, mice (22-25 g) were treated
with siRNA against SphK1 (n = 12 mice/group) or SphK2 (n = 7 mice/group) (5
µg/animal; equivalent to 200 µg/kg, in 0.2 ml final volume of PBS) i.p. on days 20-22,
and then once every 2 days until day 45. Control mice (n = 12 mice/group) received
scrambled siRNA at the same time points. The dose of siRNA chosen is consistent
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with our previous in vivo murine studies (typically 4-8 µg/animal) (23, 24). The level
of SphK1 and SphK2 inhibition was assessed by western blot in spleen cells freshly
isolated from mice treated with either SphK1, SphK2, or scrambled control siRNA.
Mice were sacrificed 24 hours after the last treatment and cell lysates were separated
by 10% SDS-PAGE, transferred onto membrane and probed with specific anti-SphK1,
anti-SphK2, or control Abs GAPDH and α-Tubulin as described below (section 2.6.2)
(94).
2.4.3 Monitoring progression of CIA
Arthritis progression was monitored daily using the following criteria:
incidence of arthritis
number of limbs involved.
mouse footpad diameter – dial caliper measurement (Kroeplin, Germany)




Swelling and erythema (2)
Erythema, swelling, and extension/ loss of function (3)
2.4.4 Quantification of Paw histology
At the end of the experiments hind limbs were removed above the knee and
immediately fixed in 10% neutral-buffered formalin (J.T. Baker, New Jersey, USA)
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for at least 72 hours. Paws were decalcified in 5% HNO3 for a further 72 hours, then 5
µm sections were cut using a bone cryostat. Sections were stained with hematoxylin
and eosin (H&E; Sigma-Aldrich, USA) using the standard method. Quantification of
arthritis was performed by two treatment blind observers using the scoring system
described by Joosten et al. (280). Briefly, the extent of inflammation, synovial
hyperplasia and joint erosion was graded separately. For synovial infiltration and
hyperplasia, a scale of 0-3 (0; normal, 1; mild, 2; moderate, and 3; severe) was
established according to the amount of inflammatory cells in the synovial tissue. Joint
destruction was scored on a scale of 0-3, ranging from area with dead chondrocytes to
complete loss of articular cartilage. Scored were pooled and means ± SD were
obtained.
2.4.5 Induction of Asthma in mice- Sensitisation and challenge with OVA
Female BALB/c mice at 8- to 10-wk-old were obtained from the Laboratory Animals
Centre, National University of Singapore. Animals were housed in the Animal
Holding Unit, NUS, and all experiments were conducted according to the Institutional
Guidelines for Animal Care and Use Committee for National University of Singapore.
Mice were immunised with fraction V OVA (100 µg; Sigma-Aldrich) in an alum
suspension (2% Imject Alum; Pierce) in a volume of 200 µl by i.p. injection on days 0
and 14. On day 14, mice were anesthetised and 100 µg of OVA in 50 µl of PBS
administered intranasally (i.n.) in a dropwise manner. Mice were again anesthetised
before being challenged with 50 µg of OVA in 50 µl of PBS on each of days 25–27.
Control mice were given PBS in place of OVA in both the i.n. sensitisation and
challenge stages of the protocol.
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2.4.6 Asthma model: Treatment protocols
DMS (n = 15 mice/group) (200 or 400 µg/kg) was given by i.p. injection 30 minutes
before the OVA challenge on days 25–27. Control mice (n = 14 mice/group) received
PBS supplement with ethanol as carrier control. Similarly, siRNA against SphK1 (n =
5 mice/group) or scrambled control (n = 5 mice/group) (5 µg/animal; equivalent to
200 µg/kg) was given i.n. on days 21 and 23 and subsequently 1 h before each OVA
challenge on days 25–27. The level of SphK1 and SphK2 inhibition was assessed by
western blot in PBMC and lung cells freshly isolated from mice treated with either
SphK1, or scrambled control siRNA. Mice were sacrificed 24 hours after the last
treatment and cell lysates were separated by 10% SDS-PAGE, transferred onto
membrane and probed with specific anti-SphK1, anti-SphK2, or control Abs GAPDH
and α-Tubulin.
2.4.7 Bronchoalveolar lavage (BAL) process
BAL was performed 24 hours after the last OVA challenge. Mice were anesthetised
and thoracic cavity was opened by careful dissection. The trachea was then exposed,
and a small transverse incision made just below the level of the larynx. BAL was then
performed using two doses of 0.5 ml of PBS, ensuring that both lungs inflated during
the lavage process and that there was no leakage of lavage fluid from the trachea. The
lavage samples from each mouse were pooled and kept on ice until processing. BAL
fluid was centrifuged at 400 g for 5 min, and the supernatant was removed and stored
at -80°C until assay of cytokines. BAL cell number was determined using a
hemocytometer. Cytospin preparations were made using a Cytospin (Cyto-Tek,
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Sakura). Briefly, cell suspensions of not more than 5 x 105 cells/ml in PBS were
prepared. The slides were pre-labeled before mounting with the paper pad and the
cuvette in the metal holder. 200 µl of the cell suspensions were loaded in each cuvette
and spin at 1000 rpm for 10 minutes. After the spin, the cuvette and the paper were
carefully detached without damaging the fresh cytospin and the area around the
cytocentrifuged cells was marked with a permanent marker. These slides were quickly
air-dried, and then stained with a modified Wright stain. Differential cell counting
was performed using standard morphological criteria in which 300 cells were counted
per slide.
2.4.8 Lung histology
After BAL sampling had been completed, the lungs were removed from the thoracic
cavity by careful dissection. The lungs were inflated with 1 ml of 10% neutral-
buffered Formalin and then fixed in 10% neutral-buffered Formalin for 72 h. After
fixation, the left lung was dissected free and embedded in paraffin, and 6-µm sections
were cut. Sections were then stained with H&E. Total lung inflammation was defined
as the sum of the peribronchial plus perivascular scores. The severity of peribronchial
and perivascular inflammation was graded semiquantitatively for the following
features: 0, normal; 1, few cells; 2, a ring of inflammatory cells 1 cell layer deep; 3, a
ring of inflammatory cells 2– 4 cells deep; 4, a ring of inflammatory cells of >4 cells
deep. Mucus production and goblet cell hyperplasia was examined by periodic acid-
Schiff (PAS) staining as described previously (281). The numerical scores for the
abundance of PAS-positive mucus-containing cell as a proportion of the section area
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viewed under microscope in each airway were determined as follows: 0, < 5% PAS-
positive cells; 1, 5–25%; 2, 25–50%; 3, 50 –75%; 4, >75%.
2.4.9 Measurements of airway hyperresponsiveness (AHR)
Mouse airway responsiveness to methacholine (Sigma-Aldrich) was measured using
an invasive system previously described (282). Briefly, mice were anesthetised and
tracheotomy was performed. The internal jugular vein was cannulated and connected
to a microsyringe for i.v. methacholine administration. The mouse was then placed in
a whole-body plethysmograph chamber (Buxco Electronics) and ventilated
mechanically by a rodent ventilator (Hugo Sachs Elektronik; Harvard Apparatus) at a
tidal volume of 200 µl/breath and a respiratory rate of 150/min. Transpulmonary
pressure was measured as airway opening pressure referenced to pressure within the
chamber. Lung volume changes were measured by detecting pressure changes in the
plethysmographic chamber. Flow was measured by differentiation of the volume
signal. Pressure, flow, and volume changes were recorded and analysed by the
BioSystem XA software (Buxco Electronics). Lung resistance was continuously
computed by fitting flow, volume, and pressure to an equation of motion. Acetylb -
methacholine (Sigma-Aldrich, USA) was dissolved in normal saline and administered
intravenously at a starting dose of 5 µg/kg. The average volume per methacholine
dose was approximately 35 µl. Threefold-increasing concentrations of methacholine
were administered at 2-minutes intervals, and only after transpulmonary pressure and
tidal volume returned to within 10% of baseline. Pulmonary variables were recorded
for at least 10 breaths during the peak response, within 30 seconds after each
intravenous methacholine dose. Methacholine dose–response curves were obtained by
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calculating the mean ± standard error for individual animals at each methacholine
dose. The highest value of lung resistance (RL) and the lowest value of dynamic
compliance (Cdyn) for each methacholine dose were chosen and expressed as a
percentage of the respective basal values in response to PBS.
2.4.10 Serum collection
For the asthma model, blood was collected by cardiac puncture immediately after the
thoracic cavity was opened 24 hours after the last OVA challenge. For the CIA model,
serum was collected using cardiac puncture on day 27 before onset of clinical arthritis
and at day 46. Blood was allowed to clot, then centrifuged and aliquots of serum
stored at -80°C before cytokines, S1P and anti-collagen Ab levels analysis by ELISA
(section 2.5).
2.5 ELISA assays
2.5.1 Measurement of S1P by ELISA
S1P levels in synovial fluid of RA/OA patients, and serum from DBA/1 mice were
analysed using a S1P competitive ELISA kit (Echelon Biosciences Inc, Utah, USA)
according to manufacturer’s instructions. Sensitivity of the assay was 30 nM. Briefly,
the pre-coated microtiter plate (Nunc, Maxisorp) was blocked with 150 µl of block
solution for 1 hour at room temperature.  After 4 washes, diluted anti-S1P antibody
was added to the diluted samples at 1:4 ratio and mixed for 5 minutes before adding
them into the microtiter plate. The plate was further incubated for 1 hour at room
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temperature. The plate was then washed four times, and 100 µl/well diluted
streptavidin-HRP (Pharmingen, BD Biosciences) was added to each well of the coated
microtiter plate and incubated at room temperature for 1 hour. Finally, the plate was
washed four times before 100 µl of 3,3',5,5'-tetramethylbenzidine (TMB; Sigma-
Aldrich, USA) peroxidase substrate was added to each well. The reaction was stopped
with 100 µl/well of H2SO4. Plates were read at 450 nm (reference filter 570nm) using
an automatic ASYS UVM 340 microplate reader.
2.5.2 Measurement of antigen-specific serum IgG isotypes by ELlSA
96-well immuno-plates (Nunc, Maxisorp) were coated overnight at 4°C with 50 µl of
a 2 µg/ml solution of OVA or CII in 0.05 M bicarbonate buffer. After three washes
with PBS/0.05% Tween 20, nonspecific protein- binding sites were blocked with 100
µl/well PBS/5% FCS (GIBCO® Invitrogen, Singapore) for 2 hours at room
temperature. After two washes with PBS/0.05% Tween 20, 50 µl aliquots of test sera
in doubling dilutions (1:20 to 1:2560) in PBS/10% FCS were added to the plate and
incubated at room temperature for 2 hours. After four washes, biotinylated rat anti-
murine IgGl, IgG2a or IgE (all from BD Biosciences) diluted 1:1000 in PBS/10%
FCS were added at 50 µl/well and incubated for 1 hour at room temperature. Plates
were then washed four times, and 50 µl/well avidin-peroxidase (Pharmingen, BD
Biosciences) in PBS/5% FCS was added at 2 pg/ml. After a final incubation for 30
minutes at room temperature, the plates were washed six times, before 100 µl of TMB
was added to each well. The reactions were stopped with 100 µl/well of H2SO4. Plates
were read at 450 nm (reference filter 570nm) using an ASYS UVM 340 microplate
reader.
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2.5.3 General ELISA protocol
Cytokines were detected in culture supernatant or biological fluids by sandwich
ELISA, with paired capture and biotinylated detection monoclonal antibodies for each
cytokine. Human IL-1ß, IL-6, TNF-α, MCP-1 (all Pharmingen, BD Biosciences), and
MMP-9 (GE Healthcare, UK) assays were performed according to manufacturers’
instructions. Detection limits were as follows: IL-1ß, IL-6, TNF-α, MCP-1 all at 10
pg/ml; MMP-9 at 2 ng/ml. Similarly for murine ELISA, the antibody pairs for TNF-α,
IFN-γ, IL-4, IL-5, IL-6, and IL-10 were obtained from BD Biosciences, and eotaxin
from R&D systems, USA. The lower limit of detection for murine TNF-α, IL-4, IL-5,
IL-6, IL-10, and eotaxin was 10 pg/ml, and that for IFN-γ was 40 pg/ml. Wash buffer
used was 1 x PBS/0.05% Tween 20. Briefly, Nunc-immuno plates were coated
overnight at 4°C with capture antibody at 2 µg/ml in bicarbonate coating buffer. The
plates were washed two times before blocking with PBS/10%FCS for 2 hours at room
temperature. The plates were washed a further two times before incubation with test
samples, or two fold standard dilutions of recombinant cytokine (10 ng/ml to 10 µg
/ml) in triplicates for 2 hours. The plates were washed four times and bound cytokines
were detected for 1 hour with 1 µg /ml biotinylated detection monoclonal antibody
diluted in blocking buffer. Another four washes were done before peroxidase-
conjugated avidin was added for 30 minutes (1:1000 dilution). Finally, the plates were
washed six times and developed with 100 µl TMB substrate for 10 to 30 minutes until
the color change was completed. The reaction was then stopped with 100 µl 1M
H2SO4. ODs of the samples are taken at 450nm with reference range at 570nm using
ASYS UVM 340 microplate reader. The specific amount of cytokine in each sample
are then determined from the standard curve generated.
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2.6 Western blot
2.6.1 Lysis with radio-immunoprecipitation assay (RIPA) buffer
RIPA buffer enables the extraction of cytoplasmic, membrane and nuclear proteins.
Protease and phosphastase inhibitor cocktail (Both from Roche Diagnostics, Germany)
solutions were added to 1x RIPA buffer to prepare complete RIPA lysis buffer just
prior to usage. Briefly, the cells were washed at least 2 times in ice-cold PBS before
centrifuging at 1000 rpm for 4 minutes to collect the cell pellets. Approximately 100
μl/million cells of complete RIPA lysis buffer was added to each sample. The cell
lysates were passed through a p200 pipette tip 20 times to form homogeneous lysates
and then allowed to stand for 30 minutes on ice. Finally, the lysates were centrifuged
at 13,000g for 10 minutes at 4°C to separate cell debris from protein. The
supernatants were then transferred to new 1.5 ml tubes and stored at -20°C until
analysis with Western blot.
2.6.2 General protocol for western blot
Western blot analysis for SphK1 and SphK2 levels was conducted in PBMC, lung and
spleen tissues freshly isolated from mice treated with either SphK1, SphK2 or
scrambled control siRNA (5 µg/animal/day), and in HL60 and U937 cells treated with
either SphK1 or scrambled antisense oligonucleotides (10 µM) . Mice were sacrificed
24 h after the last treatment and the cells were lysed in RIPA buffer. Unless stated
otherwise, 80µg of lysate for each sample was resolved on 12% polyacrylamide gels
(SDS–PAGE) under denaturing conditions and then transferred to 0.45-mm
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nitrocellulose membranes. After blocking for 2 hours at room temperature with 5%
non-fat milk in TBS/0.1% Tween 20, the membranes were incubated overnight with
the relevant primary antibodies at 4°C. The membranes were washed extensively in
TBS/0.1% Tween 20 (washing buffer) before probing with the corresponding HRP-
conjugated secondary antibodies for 2 hours at room temperature. After which, the
membranes were washed and developed with the ECL Western Lightning
Chemiluminescence (PerkinElmer, Massachusetts, USA) and Kodak films.
The membranes were probed with specific anti-SphK1, anti-SphK2 (both from
Exalpha Biologicals, Inc., Massachusetts, USA), or control Abs GAPDH and α-
Tubulin (both from Santa Cruz Biotechnology, Inc., California, USA ) as
summarized in table 2.1. Anti-rabbit and anti-goat HRP-conjugated secondary
antibodies were purchased from Thermo Scientific. Anti-mouse HRP-conjugated
secondary antibody was purchased from Sigma-Aldrich.
2.7 Statistical analysis
Clinical and histological scores, BAL total/differential cell counts, and S1P levels in
the serum and synovial fluid were analysed with the non-parametric Mann-Whitney
U-test. Differences between cumulative incidences of arthritis at a given time point
were analysed by the chi-square contingency analysis. BAL and serum cytokines,
collagen/OVA-specific IgG and IgE antibody levels, and AHR response were
compared using the Student’s t-test. Cytokines, MMP, and β-hexosaminidase levels
from cell-contact assays, and cytokines levels from antigen-specific in vitro cultures
were compared using 2-tailed Student’s t-test unless stated underwise.
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Mouse IgG (H+L) Goat polyclonal 1/2000 Sigma-Aldrich
h- human; c-term- c-terminal; FL- full length; H+L- heavy + light chains
65
















Sphingolipids are ubiquitously expressed in all eukaryotic cell membranes. Over the
past few years, it has become clear that sphingolipids are sources of important
signalling molecules in addition to their roles as structural components of the
membranes. In particular, sphingolipid metabolites such as ceramide and sphingosine-
1-phosphate (S1P), have emerged as a new class of potent bioactive messengers
involving in an array of cellular processes, including cell differentiation, proliferation
and apoptosis (283, 284). Recently, interest in S1P focused on two distinct cellular
roles, namely its function as an intracellular second messenger, or extracellularly as a
specific and high affinity ligand for a family of G protein-coupled receptors
previously known as the endothelial differentiation gene (EDG) family. To date, five
S1P receptors have been identified, which include, EDG-1, EDG-3, EDG-5, EDG-6
and EDG-8, these receptors are now collectively known as S1P1-5 receptors (11, 13,
20).
As an intracellular second messenger, S1P was found to play a role in Ca2+ signalling
and mobilisation, cell proliferation and survival. Activation of various plasma
membrane receptors, such as the platelet-derived growth factor receptor (21, 22),
FcRI and FcRI antigen receptors (23-25), the fMLP receptor (26), the C5a receptor
(27, 28), and TNF- receptor (29), leads to rapid increase in intracellular S1P level
via sphingosine kinase (SphK) stimulation. Inhibition of SphK stimulation strongly
reduced or even prevented cellular events triggered by these receptors, such as
receptor-stimulated DNA synthesis, Ca2+ mobilisation, and vesicular trafficking (21-
26). It has previously shown that inhibition of SphK activity, by N,N-
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dimethylsphingosine (DMS), a potent SphK inhibitor, leads to reduced Ca2+
mobilisation, enzyme release, chemotaxis, cytokine and chemokine production in
human neutrophils, monocytes and macrophages (27, 28). Moreover, by using a
specific anti-sense knockdown approach, SphK1, one of the two cloned human SphK
isoforms, was found to be a critical regulator in TNF- mediated pro-inflammatory
responses in human monocytes (29).
Asthma is a chronic allergic disorder characterised by airway hyperresponsiveness
(AHR), inflammatory infiltrates in the bronchial walls containing eosinophils, and
elevated serum IgE levels. Lung biopsies of asthmatic patients have revealed
pulmonary infiltration of lymphocytes, particularly of the T-helper 2 (Th2) type,
macrophages and mast cells. These cells, together with the resident airway cells,
interact with one another to initiate and perpetuate allergic airway inflammation
(206) . Th2 cytokines such as interleukin (IL)-4, IL-5 and IL-13 play a critical role in
promoting airway inflammation and are required for the development of airway
eosinophilia and IgE production (203-205). Eotaxin, a C-C chemokine, is highly
expressed in asthmatic airway epithelium and is pivotal for the recruitment of
eosinophils (242-244). Thus, it has been proposed that airway eosinophilia together
with various inflammatory cytokines as described above may contribute to eventual
AHR in asthma.
S1P promotes monocytes and lymphocyte activation and migration (8, 48, 285, 286),
and mast cells degranulation and chemotaxis (23, 25, 83). Local administration of S1P
causes inflammation coupled with eosinophil recruitment in a rat-paw model, which
can be inhibited by anti-CCR3 Ab (50). Moreover, elevated levels of S1P in
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bronchoalveolar lavage (BAL) fluid were recovered from allergic asthma patients
after ragweed antigen (Ag)-challenge and may play a role in both acute
bronchoconstriction and airway remodelling through its direct action on airway
smooth muscle (ASM) cells (263, 287). In a murine model of asthma, S1P causes a
dose-dependent contraction of bronchi and triggers AHR in OVA-sensitised mice, and
is coupled to an enhanced expression of SphK1, SphK2, and S1P2 and SIP3 receptors
(288). In addition, SIP has been proposed to be a key regulator of Th2 lymphocyte
trafficking in an OVA-induced food allergy model in mice (289). Murine allergic
asthma represents an ideal model to explore the diverse inflammatory effects of SphK
blockade. Using a murine model of allergic asthma, immune-modulatory effects of
inhibition of SphK activity, either by DMS or specific targeting of SphK1 by siRNA
approach, was investigated. Both DMS and SphK siRNA can effectively suppress
eosinophilic airway inflammation, Th2 cytokine and chemokine secretion and
markedly attenuated OVA-induced AHR in sensitised animals. These data identify
SphK as a potential therapeutic target in allergic asthma.
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Results
3.1 DMS reduces BAL inflammatory infiltrates in OVA-induced asthma mice
To determine the role of SphK in OVA-induced airway inflammation, mice were
given DMS by intraperitoneal (i.p.) injection 30 minutes before intranasal (i.n.) OVA-
challenges (days 25-27). DMS is a non-phosphorable analogue of sphingosine and a
potent inhibitor of SphK. It inhibits SphK activity by competing with sphingosine to
bind to SphK and has been used in a number of in vitro and in vivo studies for this
purpose (23-28, 290). BAL was collected 24 hours after the last OVA challenge, and
total and differential cell counts were performed. Intranasal OVA challenge induced
significant increases in total cell, eosinophil, macrophage, and lymphocyte counts as
compared to saline control (p < 0.05, Fig. 3.1). DMS at both 200 g/kg and 400 g/kg,
produced a significant, dose-dependent reduction in BAL total cell count, eosinophil,
and macrophage count (Fig. 3.1, A - C). DMS at 400 µg/kg was also associated with a
significant reduction in BAL lymphocyte count (Fig. 3.1D). Consistent with previous
studies demonstrating the role of SphK/S1P in leukocyte chemotaxis, these data
suggest that SphK may play an important role in inflammatory cells recruitment into
the airways in this particular murine model of OVA-induced asthma.
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Figure 3.1 Effects of N,N-dimethyl-sphingosine (DMS) on BAL fluid cell and
differential cell count
BALB/c mice were sensitised with OVA and allowed time to develop the antigen
specific responses before challenging again with OVA i.n. on 3 consecutive days
(days 25-27). Mice were treated daily 30 minutes before each OVA-challenge with
increasing doses of DMS, 200 g/kg, n = 15; 400 g/kg, n = 15 or PBS/EtOH as
carrier control (n = 14). Naïve mice (n = 12) were given PBS in place of OVA in both
the i.n. sensitisation and challenge stages. BAL cell counts were performed on day 28.
Treatment with DMS resulted in a significant reduction in total cell count (A),
eosinophilia (B), macrophage (C), and lymphocyte numbers (D) when compared with
PBS controls (*, p < 0.05 vs PBS control, by Mann-Whitney U test). Data are
expressed as the mean ± SEM.
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3.2 DMS suppresses inflammatory infiltration and mucus production in the lung
tissue
Next, lung tissue was removed 24 hours after the last OVA challenge for histological
examination. Using H&E staining, OVA challenged mice displayed extensive
inflammatory infiltrates into both peribronchiolar and perivascular connective tissues
as compared with saline challenge (Fig. 3.2, A and B). DMS (400 g/kg) markedly
attenuated OVA-induced inflammatory infiltrates as compared with PBS carrier
control (Fig. 3.2D). DMS recipients at 200 µg/kg were associated with a mild but
non-significant reduction in inflammatory scores (p > 0.05, Fig. 3.2C). Furthermore,
by PAS staining, significant reduction in histological scoring for mucus production
and goblet hyperplasia were evident in mice treated with DMS (400 g/kg) than in
OVA control (Fig. 3.2E). These results indicated that apart from leukocyte
recruitment, SphK activity might directly influence mucus secretion in the lungs by
activating goblet cells, or indirectly by reducing level of Th2 pro-inflammatory
cytokine, IL-4 (Fig 3.3).
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Figure 3.2 Histological evidence of decreased lung inflammation and mucus
production in mice treated with DMS
Lung tissues were fixed 24 hours after the last OVA challenge, sectioned and stained
with H&E for histological assessment or periodic acid-Schiff for mucus production;
magnification, x200. A representative H&E section from each group of mice is shown.
A, Naïve mouse with PBS challenge, B, OVA-challenged mouse with peribronchial
and perivascular inflammatory infiltrates, together with eosinophilia and mucosal
hyperplasia. C, OVA-challenged mouse treated with 200 g/kg of DMS, and D, 400
g/kg of DMS; a reduction in inflammation is seen compared with B. E, Histological
appearances were scored for the presence of peribronchial and perivascular
inflammation, mucus production and goblet cell hyperplasia. Naïve mice (n = 7),
OVA-PBS treated mice (n = 9), DMS recipients, 200 g/kg (n = 10), and 400 g/kg,
(n = 10). Data are mean ± SEM, *, p < 0.05 vs PBS, by Mann-Whitney U test.
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3.3 DMS treatment reduces Th2 cytokine levels in BAL
IL-4 and IL-5, and eotaxin are critical Th2 cytokines and chemokine abundantly
present in asthmatic airways, playing key roles in driving asthma pathogenesis
(reviewed in chapter 1.6). The ability of SphK to modulate cytokine production has
been demonstrated in several in vitro and in vivo models of inflammation as discussed
previously. To determine the effect of SphK inhibition on cytokines levels in vivo,
BAL fluid samples were collected 24 hours after the last OVA challenge.
Intraperitoneal administration of DMS produced a dose-dependent reduction in the
levels of IL-4, IL-5 and eotaxin in BAL fluid when compared with PBS carrier
control (Fig. 3.3). IFN- was absent. To determine if SphK modulates B cell function
in this model, we investigated B cell antibody responses in the asthmatic mice. Blood
was collected by cardiac puncture 24h after the last OVA challenge and allowed to
clot in order to obtain the serum. However, it was found that intraperitoneal
administration of DMS did not modify the levels of OVA-specific serum IgG1, IgG2a
and IgE assayed using ELISA (data not shown).
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Figure 3.3 DMS reduces IL-4, IL-5 and Eotaxin levels BAL fluid
BAL fluids were collected 24 hours after the last OVA challenge and levels of IL-4,
IL-5 and eotaxin were determined by ELISA. Administration of DMS at 200 g/kg
and 400 g/kg dose-dependently reduced levels of IL-4 (A), IL-5 (B) and Eotaxin (C)
in the BAL fluid. Data are expressed as the mean ± SEM of individual measurements
(n = 9). *, p < 0.05 vs PBS, by Student’s t test.
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3.4 DMS suppresses OVA-specific responses in vitro
The data so far suggest that SphK plays a pro-inflammatory role in OVA-induced
asthma and that inhibition of SphK activity by DMS attenuates the inflammation.
However, it remains unclear if DMS treatment is causing global or Ag-specific
immunosuppression. From the above observations, it seemed likely that the polarity
of OVA-specific responses had been modified by transient DMS treatment during the
intranasal Ag exposure. Therefore I examined the OVA-specific immune responses in
thoracic lymph node cultures to assess whether DMS treatment directly influenced
lymphocyte function. The OVA-specific proliferation and production of IL-4 and IL-5
were significantly reduced in DMS recipients, either 200 or 400 µg/kg
intraperitoneally, in a dose-dependent manner (Fig 3.4, A, B and C). In addition,
OVA-specific IFN- was found to be slightly elevated in mice treated with 400 µg/kg
of DMS (Fig. 3.4D). Furthermore, concanavalin A (Con A) -induced production of
IL-4, IL-5, and IFN-γ in parallel cultures was not affected. Together, these data
indicate that immune modulation by DMS in vivo was indeed antigen-specific.
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Figure 3.4 Reduced in vitro OVA-specific responses in mice treated with DMS
Thoracic lymph node cells (n = 5 mice/group) were harvested from mice on day 28
and cultured for up to 96 hours with medium alone or OVA (200 g/ml). A, T cell
proliferation was assayed by Alamar blue after 96 hours. B, C, and D, Cytokine
concentrations (IL-4, IL-5 72 hours; IFN- 96 hours) in culture supernatant were
determined by ELISA. Significant suppression in OVA-induced cytokine production
and proliferation was observed in lymph node cultures removed from DMS-treated
mice compared with PBS carrier controls. *, p < 0.05 vs PBS, by Student’s t test. Data
are expressed as the mean ± SD of triplicate cultures of pooled lymph node cell
suspensions.
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3.5 DMS treatment reduces lung resistance in vivo
The effect of DMS on the development of AHR in response to increasing
concentrations of methacholine was examined. Sensitised BALB/c mice challenged
with 1% OVA aerosol for 20 minutes daily for 3 consecutive days developed AHR to
methacholine. Airway responsiveness was determined by resistance (RL), and
compliance (Cdyn). RL is defined as the pressure driving respiration divided by flow.
Cdyn refers to the distensibility of the lung and is defined as the change in volume of
the lung produced by a change in pressure across the lung. OVA-challenged mice
developed AHR which was typically reflected by high RL and low Cdyn (Fig. 3.5 A
and B). DMS significantly suppressed methacholine-induced AHR in a dose-
dependent manner, with 400 g/kg of DMS exhibiting a greater reduction in RL and
increase in Cdyn, suggesting OVA-mediated pathology in vivo was modified (Fig.
3.5).
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Figure 3.5 DMS dose-dependently reduces airway hyperreactivity in OVA-
challenged mice
Airway responsiveness of mechanically ventilated mice in response to intravenous
methacholine was measured 24 hours after last OVA challenge with pretreatment of
PBS (n = 5), DMS at 200 g/kg (n = 4), DMS at 400 g/kg (n = 5) or naïve PBS
control (n = 5) as described in materials and methods. AHR is expressed as
percentage changes from baseline level of (A) lung resistance (RL), and (B) dynamic
compliance (Cdyn). Data are expressed as the mean ± SEM of individual
measurements. *, p < 0.05 vs PBS, by Student’s t test.
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3.6 Treatment with SphK1-siRNA suppresses eosinophilic airway inflammation
DMS is a potent pharmacological inhibitor of SphK but it is not absolutely specific.
Moreover, to date, two mammalian SphK isoforms have been identified - SphK1 and
SphK2. From previous publications (25, 27-29), SphK1 isoform appears to be the
main player in inflammation. To verify that the inhibitory effects of DMS from the
above observations were indeed mediated by direct SphK inhibition rather than non-
specific off-target side effects (34), and to determine whether specific SphK1 isoform
inhibition could influence OVA-induced airway inflammation, the siRNA knockdown
approach was used. BALB/c mice were given intranasal 200 µg/kg of SphK1 siRNA
or scrambled siRNA as control on day 21 and 23, and subsequently 1 hour before
each intranasal OVA-challenge (days 25-27). In accordance to the previous DMS
results, SphK1 siRNA treated animals exhibited a significant reduction in BAL total
cell count and eosinophilia (Fig. 3.6, A and B) as compared to control mice that
received scrambled siRNA. In addition, a moderate but non-significant reduction in
macrophage and lymphocyte counts was observed in SphK1 siRNA treated mice (p >
0.05, Fig. 3.6, C and D). Finally, to confirm the specificity of the inhibition, the
protein expression of SphK1 and SphK2 in both lung lysates and PBMCs pre and
post-treatment was studied. Fig. 3.7A shows SphK1 protein expression in the lung
lysates of BALB/c mice was effectively blocked by 3 daily administration of SphK1
siRNA while SphK2 remains unaffected, suggesting the siRNA is specifically
knocking down SphK1 isoform but not affecting SphK2 isoform. Similarly, SphK1
protein expression in PBMCs of these animals was effectively inhibited by SphK1
siRNA treatment (Fig. 3.7B). Equal loadings of proteins were confirmed using -
tubulin as an internal control.
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Figure 3.6 Total BAL cellularity and differential cell count after treatment with
SphK1-siRNA
BALB/c mice were sensitised with OVA and then challenged with i.n. OVA as
described in materials and methods. Mice were treated i.n. on days 21, 23 and
subsequently 1 hour before each OVA challenge on days 25, 26, and 27 with 200 g/kg
SphK1-siRNA (n = 5) or scrambled control (n = 5). BAL cell counts were performed
on day 28. Treatment with SphK1-siRNA resulted in a significant reduction in total cell
count (A) and eosinophilia (B) compared with control siRNA. There was no significant
difference in macrophage (C) or (D) and lymphocyte numbers. (*, p < 0.05 vs control
siRNA, by Mann-Whitney U test). Data are expressed as the mean ± SEM.
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Figure 3.7Western blot analysis of SphK1 expression after siRNA treatment
Representative Western blot analysis of SphK1 expression in lung lysates (A) and
PBMCs (B) of BALB/c mice before and after SphK1 siRNA or control siRNA
treatment. Lane 1, Untreated control; Lane 2, daily administration of 200 g/kg SphK1
siRNA to the mice for one day, two days (Lane 3) and three consecutive daily treatment
(Lane 4). Lung lysates were probed for SphK1 isoform (42kDa) and SphK2 isoform





3.7 SphK1 siRNA treatment reduces Th2 cytokine levels in BAL
Finally, in order to determine whether specific targeting of SphK1 with siRNA could
modify OVA-specific response in vivo, BAL fluid and serum samples were collected
24 hours after the last OVA challenge and assayed for Th2 cytokines using ELISA.
Intranasal administration of SphK1 siRNA significantly reduced levels of IL-4, IL-5
and eotaxin in BAL fluid (Fig.3.8, A - C) as compared with scrambled siRNA control.
Figure 3.8 BAL IL-4, IL-5, and Eotaxin levels in mice treated with SphK1-siRNA
BAL fluids were collected 24 hours after the last OVA challenge and levels of (A) IL-
4, (B) IL-5 and (C) eotaxin were determined by ELISA. Data are expressed as the
mean ± SEM of individual measurements (n = 5). *, p < 0.05 vs control siRNA, by
Student’s t test.
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3.8 SphK1 siRNA treatment reduces serum IgE levels
Serum levels of OVA-specific IgE were also significantly reduced in SphK1 siRNA
treated mice (Fig. 3.9), whereas OVA-specific IgG1 and IgG2a were found to be
similar. These data together clearly demonstrate that SphK inhibition, either in the
form of DMS administration or targeting of SphK1 via siRNA, can directly modulate
the progression of airway inflammation.
Fig 3.9 Serum OVA-specific IgE levels in mice treated with SphK1-siRNA
Serum were collected 24 hours after the last OVA challenge and levels of OVA-
specific IgE were determined by ELISA. Data are expressed as the mean ± SEM of
individual measurements (n = 5). *, p < 0.05 vs control siRNA, by Student’s t test.
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Discussion
The prevalence of asthma is increasing in many developed nations. Consequently,
there is an urgent need for the discovery of new agents for the treatment of asthma,
especially for patients who respond poorly to conventional therapy such as
corticosteroids. Elevated levels of S1P in BAL fluid were recovered from allergic
asthma patients after ragweed Ag-challenge and may play a role in both acute
bronchoconstriction and airway remodelling through its direct action on ASM cells
(263, 287). In this chapter, I have demonstrated that blockade of SphK activity, either
by DMS, or specific siRNA targeting of SphK1, can effectively suppress airway
inflammation, Th2 cytokine and chemokine secretion, and markedly attenuated OVA-
induced AHR in sensitised animals. These data indicate that SphK pathways may find
therapeutic utility in allergic asthma.
Sphingolipids have been identified as important sources of signalling molecules in
addition to their roles as structural components of the membranes. In particular,
sphingolipid metabolites such as S1P can promote monocyte and lymphocyte
activation and migration (8, 48, 285, 286, 289), and mast cell degranulation and
chemotaxis (23, 25, 83, 289). Data presented here indicate that DMS has an inhibitory
action on inflammatory cells infiltration into the lungs and mucus production, as
revealed by histological examination, and by a significant drop in total cells and
eosinophil counts in BAL fluid. This suppressive action of DMS on leukocyte
migration is consistent with previous studies showing that SphK play a role in
chemotaxis of human peripheral blood neutrophils, macrophages and eosinophils (27,
28, 50, 290). Inhibition of SphK may have a direct effect on cellular migratory
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machinery such as Ca2+ mobilisation and expression of adhesion molecules including
VCAM-1 and E-selectin (41). Finally, indirect effect mediated through the
suppression of chemokine production is also possible as reduced eotaxin BAL levels
were observed in DMS-treated mice. The reduction in mucus production might
indicate that SphK activity can directly influence mucus secretion in the lungs by
goblet cells, or indirectly by reducing level of Th2 pro-inflammatory cytokine, IL-4
(209).
There is now clear evidence that Th2 cells play an important role in the pathogenesis
of the allergic airway inflammation (204, 206). Eosinophil transmigration into the
airways is a multistep process that is regulated by Th2 cytokines such as IL-4, IL-5,
and IL-13, as well as specific chemokines like eotaxin and adhesion molecules such
as VCAM-1 and selectins (291). Data from above show that the anti-inflammatory
effect of DMS is at least in part mediated through a suppressive action on T
lymphocytes, as OVA-specific cell proliferation, IL-4 and IL-5 productions were
reduced in thoracic lymph node cultures from DMS-treated mice. A reduction in BAL
fluid IL-4 and IL-5 levels was also observed in these mice. Finally, the reduction in
Th2 cytokine production in the thoracic lymph node cultures was accompanied by a
slight increase in the production of IFN-γ.
In addition, the anti-inflammatory effects of SphK blockade may extend to resident
ASM cells. The above results indicate that DMS significantly suppressed OVA-
induced AHR to methacholine in a dose-dependent manner. S1P has been identified
as an important factor in orchestrating both the acute asthmatic bronchoconstriction
and the chronic features of airway remodelling (263, 287, 288). Using human ASM
87
cells embedded in collagen matrices, Rosenfeldt et al. (287) have shown that S1P
induced formation of stress fibers, contraction of individual human ASM cells, and
stimulated myosin light chain phosphorylation in a Rho-kinase dependent manner.
Thus, the suppression of AHR by DMS could in part due to the direct inhibition of
ASM contraction. Moreover, IL-5 has been recognised to play an important role in
AHR by recruiting and activating eosinophils, leading to release of pro-inflammatory
products such as cysteinyl-leukotrienes and major basic protein, which are closely
associated with AHR (237, 292). As a result, the observed alleviation of AHR may be
also associated with the reduced tissue eosinophilia and Th2 cytokine levels via SphK
pathway inhibition.
It is important to establish the inhibitory effects of DMS from the above observations
were mediated by direct SphK inhibition rather than non-specific off-target side
effects (34), and to determine the efficacy of SphK1 blockade in murine asthma using
a highly specific siRNA. Intranasal administration of SphK1-siRNA substantially
reduced eosinophilic infiltration into the lungs of the asthmatic mice. Reduced levels
of IL-4, IL-5, and eotaxin were also observed in the BAL fluid of SphK1-siRNA
treated animals. IgE-mediated mast cell activation and degranulation is a hallmark of
allergic inflammation. The above data showed that serum levels of OVA-specific IgE
were reduced by SphK1-siRNA. S1P is known to play a pivotal role in the regulation
of lymphocyte emigration from organized lymphoid tissues such as lymph nodes and
thymus. It is of interest that FTY720-phosphate, which binds to S1P receptors, caused
the rapid disappearance of peritoneal B cells by inhibiting both their emigration from
parathymic lymph nodes, and reduced peritoneal B cell-derived intestinal secretory
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IgA production (293). This suggests S1P may play an important role in regulating B-
cell trafficking and antibody production.
In conclusion, I observed inhibition of SphK is effective in reducing pulmonary
inflammation and eosinophilia, AHR, BAL eotaxin, IL-4, IL-5, and serum OVA-
specific IgE levels as well as in vitro Ag-specific inflammatory responses in a murine
model of allergic asthma. This immuno-modulatory effect is likely to occur through
several different mechanisms. Elevated concentrations of SIP have been found in
BAL of patients with asthma and are regulated by the enzyme SphK. Recent data
have suggested that S1P is involved in regulating ASM contraction, and inflammatory
cells activity including mast cells, eosinophils and T cells. Furthermore, in a recent
study by Nishiuma et al. using a similar OVA-induced asthma mouse model (294),
they found that DMS or SK-I [SK-I; 2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole]
inhalation resulted in a decrease in S1P level in BAL fluid, accompanied by decreased
eosinophil infiltration and peroxidase activity. OVA-induced increase in IL-5, IL-13,
and eotaxin levels in the BAL fluid were significantly suppressed by DMS
pretreatment. Moreover, bronchial hyperresponsiveness to inhaled methacholine and
goblet cell hyperplasia were improved by SphK inhibitors. Roviezzo et al. (295)
demonstrated in Balb/c mice that S1P given subcutaneously caused a specific and
dose dependent increase in cholinergic reactivity of bronchial tissues and whole lungs
resistance in vitro. Lungs isolated from S1P-treated mice displayed an increase in
mast cell number and IL-4, IL-13 and IL-17 mRNAs. Taken together, these findings
suggest SphK pathway may represent a novel target in the treatment of asthma.
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Chapter 4




Sphingolipids are sources of important signalling molecules in addition to their role as
structural components of the eukaryotic cell membranes. Belonging to a new class of
potent bioactive molecules, ceramide and sphingosine-1-phosphate (S1P) have been
shown to be involved in a variety of cellular processes, including cell differentiation,
apoptosis and proliferation (284, 296). Interests in S1P focus on two distinct cellular
roles, namely its function as an intracellular second messenger or extracellularly as a
specific and high affinity ligand for a family of G protein-couple receptors. In total
five S1P receptors in the endothelial differentiation gene family, S1P1-5, have been
identified (11, 20, 296).
Sphingosine kinase (SphK) is a key enzyme in the sphingolipid metabolic pathway
responsible for phosphorylating sphingosine into S1P. As described in previous
chapter, two mammalian SphKs, SphK 1 and SphK 2, have been identified and
characterised (10, 30, 32). As an intracellular second messenger, S1P was found to
play a role in Ca2+ signalling and mobilisation (23, 25), cell proliferation and survival
(8). Activation of various plasma membrane receptors, such as the fMLP receptor (26),
the C5a receptor (27, 28), and TNF- receptor (29), leads to rapid increase in
intracellular S1P level via SphK stimulation. As described in the previous chapter, it
has been shown that N,N-dimethylsphingosine (DMS) treatment can lead to reduced
Ca2+ mobilisation, enzyme release, chemotaxis, cytokine and chemokine production
in human neutrophils, monocytes and macrophages via inhibition of SphK activity (27,
28, 290). Moreover, SphK1 was identified as the isoform responsible for modulating
TNF-α mediated IL-1β and IL-6 responses in human monocytes (29).
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Elevated levels of pro-inflammatory cytokines production characterise rheumatoid
arthritis (RA) synovial inflammation (99, 100). In particular, within inflamed RA
synovial membrane, the levels of pro-inflammatory cytokines (namely TNF-, IL-1
and IL-6) exceed those of anti-inflammatory agents (IL-1RA and IL-10) and this
likely contributes directly to cartilage and bone erosion through promoting matrix
metalloproteinase (MMP) production and dysregulated chondrocyte/osteoclast
function (99-101). Moreover, successful therapeutic targeting of cytokines in RA,
particularly TNF-, had demonstrated their critical pathogenic importance (100, 101,
297). The synovial cytokine response arises predominantly through the activities of
activated T lymphocytes. T cell effector function may be via cytokine secretion e.g.
IL-17, or through cell-contact dependent cognate interactions with macrophages, via
ligand pairs such as LFA-1/ICAM-1 and CD40/CD154 (122, 179, 298-300). Recently,
elevated SphK1, S1P and S1P1 levels have been detected in RA synovium, and S1P
signalling via S1P1 was found to promote synoviocyte proliferation, inflammatory
cytokine–induced COX-2 expression and PGE2 production (264, 301). In the present
chapter, I studied whether targeting SphK activity by DMS possess any immuno-
modulatory, anti-arthritic properties. It was found that synovial fluid of RA patients
exhibited higher concentration of S1P than that of osteoarthritis (OA) patients. DMS
suppressed cytokines and MMP-9 release by RA-derived PBMCs and by human
monocytic cell lines following contact-dependent interaction with activated T
lymphocytes. The potential clinical relevance of these observations is illustrated by
DMS can effectively suppress murine collagen-induced arthritis (CIA) both in vivo




4.1 Detection of S1P in RA synovial fluid
I first compared the concentration of S1P in synovial fluids collected from 14 RA
patients and 8 patients suffering from OA, a degenerative joint disease. While RA is
an autoimmune disease, OA is usually due to aging and mechanical stress on the joint,
causing the breakdown and eventual loss of the cartilage. S1P level was measured by
a competitive ELISA, and up to 17.51 ± 4.23 M (mean ± SD) of S1P was detected in
RA synovial fluids, significantly higher than those observed in OA fluids (3.45 ± 0.85
M, p < 0.05, Mann-Whitney U test, Fig. 4.1).
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Figure 4.1 S1P levels in the synovial fluid from RA and OA patients
S1P levels in synovial fluid of 14 RA and 8 OA patients were analysed using a S1P
competitive ELISA kit. Data are presented as individual samples in a dot-plot. S1P
level in RA patient is significantly higher at 17.51 ± 4.23 M (mean ± SD)  as
compared to 3.45 µM ± 0.85 M in OA patients; p < 0.05, Mann-Whitney U test.
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4.2 SphK inhibitors reduce Jurkat T cell contact-induced cytokine production
via cognate interactions in human monocytic cell line U937 and promyelocytic
cell line HL-60
T cells from RA synovium or peripheral blood (PB), particularly those activated by
phytohaemagglutinin (PHA) and phorbol 12-myristate 13-acetate (PMA), or
cytokines like IL-15 or IL-18, are capable of driving macrophages to produce TNF-
in a cell-contact dependent manner (110, 174). Some of the ligand pairs thought to be
involved in cell-contact dependent cytokine production include LFA-1 and ICAM-1,
and membrane bound TNF-a and its receptor (section 1.5.4). I therefore investigated
the ability of DMS, a potent SphK inhibitor, to influence the production of pro-
inflammatory cytokines such as TNF- by monocytes in response to activated T cells
in a cell contact co-culture system (122, 179, 300). Jurkat T cells were cultured with
PHA and PMA for 72 hr, fixed with paraformaldehyde and then co-cultured with
human U937 monocytic cells for a further 48 hr, in the presence or absence of DMS
as described in Materials and Methods section 2.3.6. Jurkat T cells not stimulated with
PHA/PMA were included as control. As expected, activated T cells induced
substantial production of TNF-, IL-1, IL-6, and MCP-1 by U937 cells (Fig.4.2 A-
D). Such cytokine synthesis was markedly reduced when the U937 cells were treated
with DMS in a dose dependent manner (Fig. 4.2 A-D).
Sphingosine kinase inhibitor 2 (SKI2) is a relatively new inhibitor of SphK that
selectively targets SphK1 isoform. The ability of SKI2 to influence the production of
pro-inflammatory cytokines by monocytes in response to activated T cells in a cell
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contact co-culture system was studied. Similarly, Jurkat T cells were cultured with
PHA and PMA, fixed with paraformaldehyde and then co-cultured with human HL-60
promyelocytic cells, in the presence or absence of SKI2. Activated T cells induced
considerable production of IL-1 and IL-6 by HL-60 cells, which were markedly
reduced in the presence of SKI2 in a dose dependent manner (Fig. 4.3 A, B).
Figure 4.2 N, N-dimethyl-sphingosine (DMS) inhibits contact-dependent cytokine
production U937 monocytes in vitro
Paraformaldehyde-fixed PMA/PHA stimulated (Ts) or medium control (Tc) Jurkat T
cells were co-cultured with U937 cells either in medium alone or with increasing
concentrations of DMS. Activated Jurkat T cells induced TNF- (A), IL-1 (B), IL-6
(C), and MCP-1 (D) production in a cell contact-dependent fashion and was
significantly inhibited by DMS in a dose-dependent manner. Data are mean ± SEM of
triplicate cultures and are representative of five similar experiments, *, p<0.05 vs
Ts/U937 by Student’s t test.
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Figure 4.3 Sphingosine kinase inhibitor 2 (SKI2) inhibits contact-dependent cytokine
production from HL-60 promyelocytic cells in vitro
Paraformaldehyde-fixed PMA/PHA stimulated (Ts) or medium control (Tc) Jurkat T
cells were co-cultured with HL-60 cells either in medium alone or with increasing
concentrations of SKI2. Activated Jurkat T cells induced IL-1 (A) and IL-6 (B)
production in a cell contact-dependent fashion and the production were significantly
inhibited by SKI2 in a dose-dependent manner. Data are mean ± SEM of triplicate
cultures and are representative of three similar experiments, *, p<0.05 vs Ts/HL-60 by
Student’s t test.
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4.3 Cell contact with inserts
Both soluble factors and cell-cell contact are important mechanisms driving pro-
inflammatory mediator production, and interplay of these mechanisms is required to
sustain chronic inflammation. To ascertain that the cell-contact is indeed essential for
the production of pro-inflammatory mediators observed in the previous results, a
semi-permeable membrane was inserted between the fixed Jurkat T cells and HL-60
cells in a co-culture system. As expected, activated T cells induced substantial
production of IL-6 and TNF-α by HL-60 cells (Fig. 4.4 A, B). Removal of contact
between the two cell types by the insert completely abolished the synthesis of pro-
inflammatory IL-6 and TNF-α (Fig. 4.4 A, B).
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Fig 4.4 Blockade of contact inhibits cytokine production from human promyelocytic
HL-60 cells in vitro
Paraformaldehyde-fixed PMA/PHA stimulated (Ts) or medium control (Tc) Jurkat T
cells were co-cultured with HL-60 cells either in medium alone or with a semi-
permeable insert separating the two cell types. Activated Jurkat T cells induced IL-6
(A), and TNF- (B) production in a cell contact-dependent fashion and the production
was abolished by a blockade of contact between the two cell types. Data are mean ±
SEM of triplicate cultures and are representative of three similar experiments, *,
p<0.05 vs Ts/HL-60 by Student’s t test.
99
4.4 DMS inhibits cell contact-induced cytokine production via cognate
interactions in PBMCs derived from RA patients
To validate the above results obtained using human cancer cell lines, PBMCs derived
from RA patients were used in identical cell contact experiments. Likewise, PB T
lymphocytes derived from RA patients were cultured with PHA and PMA, fixed with
paraformaldehyde and then co-cultured with autologous PB monocytes, in the
presence or absence of DMS. Similar data were obtained, with activated PB T cells
inducing substantial production of TNF-, IL-1, IL-6, and MCP-1 by PB monocytes,
and, DMS treatment significantly suppressing the production of these cytokines
(Fig.4.5 A-D). These results therefore demonstrate that the suppressive effect of DMS









Figure 4.5 DMS suppresses cell-mediated monocyte cytokine release induced via
cognate interactions
Cytokine production was measured in a cell contact assay in which RA patient
derived PB T cells were stimulated for 72 hours with PMA/PHA (Ts) or in medium
control (Tc), then fixed in paraformaldehyde before being co-cultured with
autologous PB monocytes with or without DMS (10 M) for 48 hours. Significant
suppression of TNF- (A), IL-1 (B), IL-6 (C), and MCP-1 (D) production in co-
culture was observed by DMS. Data are mean ± SEM from 5 RA patients, each
performed in triplicate, *, p<0.05 vs Ts/Mono by Student’s t test.
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4.5 DMS did not affect cell viability in cell-contact assays
Finally, immune modulation by DMS in vitro was unlikely due to cytotoxic effects as
cell viability, measured using the Alamar blue assay, was unaffected (Fig. 4.6). In
addition, no evidence of increased apoptosis was observed at the concentrations of
DMS employed using annexin V/7-Amino-actinomycin D staining by FACS analysis
in both U937 and RA PB monocytes; annexin V+ U937 (3.9 ± 1.7% vs DMS 10 M
3.8 ± 1.7%; 5 M 3.5 ± 1.3%; 1 M 3.9 ± 1.8%), annexin V+ RA PB monocytes (6.8
± 1.8% vs 10 M DMS 7.6 ± 2.1%), indicating that reduced cell survival is unlikely
to explain the observed inhibition.
Fig 4.6 Cell viability was unaffected by DMS treatment
After the standard cell contact experiment for 48 hours, the cells were incubated
further with Alamar blue reagent for 6 hours to measure cell viability. Cell viability
was measured as % change in OD with respect to the baseline level (U937 alone =
100%). Treatment of DMS did not significantly alter cell viability. Data are mean ±
SD, each performed in triplicate, representative of 3 separate experiments.
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4.6 DMS inhibits cell contact-induced MMP-9 production
Overproduction of MMP-9 has been observed in the synovial fluid of RA patients.
MMP-9 from macrophages and neutrophils is thought to play key roles in the
migration of these cells during inflammation in RA (302). To determine the role of
SphK in cell contact-induced MMP-9 synthesis by monocytes, Jurkat T cells or RA
PB T cells were stimulated, fixed and then co-cultured with U937 monocytic cells or
autologous PB monocytes in the absence or presence of DMS as described above.
Such co-culture-induced monocyte MMP-9 release was significantly suppressed by
DMS in a dose-dependent manner (Fig. 4.7A). Moreover, similar reduction was
observed in experiments using PB T cells and monocytes derived from RA patients
(Fig. 4.7B).
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Figure 4.7 Effect of DMS on cell-contact induced MMP-9 production by monocytes
Jurkat T cells or PB T cells purified from RA patients (n = 5) were stimulated with
PMA/PHA for 72 hours, fixed in paraformaldehyde and co-cultured with U937
monocytic cells or autologous PB monocytes in the absence or presence of DMS for
48 hours. DMS at 10 M significantly suppressed MMP-9 released by U937 cells in a
dose-dependent manner (A) or RA patients-derived PB monocytes (B). Data are mean
± SEM of triplicate cultures and are representative of five similar experiments (A) or
five RA patients (B), Ts = PMA/PMA activated T cells; Tc = medium control; *,
p<0.05 vs Ts/Mono by Student’s t test.
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4.7 Treatment with DMS did not affect cell contact-triggered degranulation
Previously, inhibition of SphK has shown to be effective in reducing degranulation in
various in vitro models such as C5a-induced degranulation in human macrophages
and neutrophils, and IgE-mediated degranulation in human bone marrow-derivedmast
cells (25, 27, 28). To investigate the role of SphK in cell contact-triggered
degranulation by monocytes, Jurkat T cells were stimulated, fixed and then co-
cultured with U937 monocytic cells in the absence or presence of DMS as described
above. Cell contact very rapidly triggered the release of ß-hexosaminidase from the
monocytes. However, addition of DMS into the co-culture did not alter degranulation
significantly (Fig. 4.8). This result indicates that SphK might not play a significant
role in cell contact-triggered degranulation by U937 cells.
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Figure 4.8 Degranulation triggered by cell contact is independent of SphK activity
Hexosaminidase release from U937 is shown as ß-hexosaminidase release from
resting cells, control (U937 alone); ß -hexosaminidase release from co-cultures with
control Jurkat cells (Tc/U937); ß -hexosaminidase release from co-cultures with
activated Jurkat cells (Ts/U937); and ß -hexosaminidase release after from co-cultures
with activated Jurkat cells in the presence of 5 and 10 µM of DMS (Ts/U937/5 and
10µM). Results are the mean ± SD of triplicate measurements and are representative
of three separate experiments.
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4.8 Treatment with DMS inhibits the development of murine CIA
I next studied the effect of DMS on the development of CIA in DBA/1 mice, a
surrogate model of human RA. Susceptible DBA/1 mice were immunised
intradermally with type II bovine collagen (CII)/CFA as described in Materials and
Methods section 2.4.1. Mice began to show clinical signs of arthritis on day 27 after
immunisation. The mice were randomly divided into the those receiving by
intraperitoneal route DMS 200 g/kg, 400 g/kg, or with PBS carrier control from
days 21-23 and then once every 2 days until day 45. The mice were monitored daily
for signs of arthritis as described in section 2.4.3.
Collagen primed mice which received DMS proved to be less susceptible to induction
of arthritis, since the incidence rate was significantly less than in the PBS carrier
control mice. The mean articular index in mice received 400 g/kg DMS was
significantly reduced. In addition, paw-swelling was markedly reduced in the mice
administered with 400 g/kg DMS relative to controls. In conclusion, DMS dose-
dependently suppressed the incident, mean articular index, and, mean paw thickness
of developing CIA (Fig. 4.9 A-C).
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Figure 4.9 DMS dose-dependently attenuated the progression of murine CIA
Collagen-primed DBA/1 mice were injected intraperitoneally with DMS 200 g/kg (n
= 16 mice/group), 400 g/kg (n = 16 mice/group) or with PBS carrier control (n = 15
mice/group) from days 21-23 and then once every 2 days until day 45. Mice were
monitored for disease progression as indicated by (A) incidence, (B) mean articular
index, and (C) mean paw thickness (mm). DMS-treated mice developed significantly
less severe disease in a dose-dependent manner compared with PBS carrier controls.
Data are mean ± SEM. *, p<0.05 vs control by Mann-Whitney U test for mean
anrticular index and mean paw thickness. *, p<0.05 vs control by chi-square
contingency analysis for % incidence.
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4.9 Treatment with DMS reduced inflammatory infiltrate into the synovium and
articular destruction
To determine whether DMS administration modified articular destruction, cartilage
and bone integrity were evaluated histologically. Mice were sacrificed and the hind
limbs removed, fixed in 10% neutral-buffered formalin, and 5 m sections were
stained with H&E. Profound adjacent cartilage and bone erosion, synovial hyperplasia,
and inflammatory infiltration into the joint compartment were clearly evident in the
PBS carrier controls (Fig. 4.10 A). DMS administration into the mice appeared to
dose-dependently reduce the joint pathology. DMS recipients at 400 g/kg markedly
attenuated cartilage and bone erosion, synovial hyperplasia, and inflammatory
infiltration into the joint (p <0.05, Fig. 4.10 C). DMS recipients at 200 µg/kg were
associated with a mild but non-significant reduction in each of these parameters (p >
0.05, Fig. 4.10 B). Together, these data clearly indicate that DMS potently suppressed
the development of CIA and such activity can prevent progression of articular damage.
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Figure 4.10 DMS treatment of mice with CIA resulted in reduced joint pathology
Hind paws were fixed, sectioned and stained with H&E for histological assessment. A
representative H&E section from each group of mice is shown (n = 6/group). A, CIA
mouse with cartilage/bone erosion, synovial hyperplasia, and inflammatory
infiltration, B, CIA mouse treated with 200 g/kg of DMS, and C, 400 g/kg of DMS;
a significant reduction in inflammation is seen compared with A. D, Histological
appearances were scored for the presence of cartilage/bone erosion, synovial
hyperplasia, and inflammatory infiltration. Data are mean ± SEM, *, p < 0.05 vs PBS,




4.10 Effect of DMS on serum cytokines, S1P and anti-CII Ab production in vivo
A potential mechanism by which SphK modulation via DMS could suppress CIA
pathology is by blocking pro-inflammatory cytokine release in vivo. To compare the
extent of such modulation, serum cytokine concentrations from arthritic mice were
measured by ELISA at the end of the treatment period (day 45). High concentrations
of IL-6, TNF-, and IFN- were detected in PBS carrier controls. These were present
at significantly (p<0.05) reduced levels in mice treated with 400 g/kg of DMS (Fig.
4.11, A-C). Moreover, reduction in serum IL-6 levels (Fig. 4.11 A), a surrogate marker
for suppression of the acute phase response, suggest that systemic inflammatory
responses were modified. Murine susceptibility to CIA is associated with high anti-
CII antibody responses (303). To determine whether DMS administration could
modify humoral response to CII, CII-specific IgG1 and IgG2a levels were also
analysed by ELISA and found to be reduced in mice treated with 400 g/kg of DMS
(Fig. 4.12, A and B). It was important to determine the degree of S1P suppression
achieved by DMS at either 200, or 400 g/kg. Thus, serum S1P levels were assessed
by ELISA and a significant reduction in S1P was observed in a dose-dependent
manner in DMS recipients (Fig. 4.13), suggesting that SphK/S1P responses were
indeed modified by the presence of DMS.
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Figure 4.11 Serum pro-inflammatory cytokines IL-6, TNF-α, and IFN-γ in DMS
treated mice
DBA/1 mice treated with DMS or PBS carrier control were sacrificed on day 45 and
serum collected from five mice in each group. Levels of IL-6 (A), TNF- (B), and
IFN- (C) were determined by ELISA of individual samples. Data are mean ± SEM.,
*, p<0.05 vs control by Mann-Whitney U test.
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Figure 4.12 Serum anti-CII IgG2a and IgG1 titres in DMS treated mice
DBA/1 mice treated with DMS or PBS carrier control were sacrificed on day 45 and
serum collected from five mice in each group. Anti-CII IgG2a (A) and IgG1 (B) Ab
levels were measured by ELISA of individual samples and expressed as mean
absorbance (OD630) ± SEM of individual serum measurements. Data are mean ±
SEM., *, p<0.05 vs control by Mann-Whitney U test.
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A
Figure 4.13 Serum S1P levels in DMS treated mice
DBA/1 mice treated with DMS or PBS carrier control were sacrificed on day 45 and
serum collected from five mice in each group. A typical S1P ELISA standard curve is
shown, with lower detection limit down to 30 nM (A). Concentration of S1P was
determined by competitive ELISA of individual samples (B). Data are mean ± SEM.,
*, p<0.05 vs control by Mann-Whitney U test.
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4.11 DMS reduced in vitro CII-specific pro-inflammatory immune responses
Next, the immunological mechanism of which SphK modulation suppresses articular
inflammation was investigated. CIA is associated with a pro-inflammatory immune
response, rendering it an excellent model to explore the effect of DMS upon
functional T cell maturation in vivo. CII-specific immune responses were examined in
vitro in pooled draining lymph node cells obtained at day 45. Cells from DMS-treated
mice produced significantly less CII-induced proliferation, IFN-, TNF and IL-6
compared with cells from control animals (Fig. 4.14 A-D) whereas anti-inflammatory
cytokine IL-10 synthesis was enhanced (Fig. 4.14E). Immune modulation by DMS in
vivo was antigen-specific since concanavalin A (Con A)-induced production of IFN-,
TNF-, IL-6 and IL-10 in parallel cultures was not affected. These data indicate that
the anti-inflammatory effect of DMS is at least in part mediated through a suppressive
action of T-lymphocytes.
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Figure 4.14 Reduced in vitro CII-specific responses in mice treated with DMS
Draining lymph node cells (n = 5 mice/group) were harvested from mice on day 45 as
described in section 2.3.4. Cytokine concentrations in the culture supernatant (72
hours for IL-6, and TNF-; 96 hours for IL-10 and IFN-) were determined by ELISA.
T cell proliferation was assayed by Alamar Blue at 96 hours (A). Significant
suppression of IFN- (B), TNF- (C), and IL-6 (D) production was observed in lymph
node cultures removed from DMS (400 g/kg)-treated mice compared with PBS
carrier controls. CII-induced production of IL-10 was significantly increased in DMS
(400 g/kg) recipients (E). Data are mean ± SD of triplicate cultures, *, p<0.05 vs
control by Student’s t test.
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Discussion
There is currently considerable interest in the potential of immuno-modulatory
therapies in the treatment of inflammatory diseases, particularly those targeting
cytokine expression. Recently, SphK and S1P were implicated in various autoimmune
conditions such as RA (264, 301, 304), primary Sjögren's syndrome (305), and
multiple sclerosis (306). The pivotal role of SphK and S1P in inflammation has been
widely established and summarized in a recent review (296). SphK/S1P has
pleiotropic effects on a variety of leukocytes such as the T and B cells (46, 48, 307),
macrophages and monocytes (28, 29), and neutrophils (27, 78, 290). Moreover,
studies have shown that SphK/S1P participates in several inflammatory responses
such as leukocyte chemotaxis (27, 28), and cytokine production and blockade of
SphK activity suppresses such responses (27-29, 290, 307). The present data indicate
that concentration of S1P in the synovial fluid of RA patients were significantly
higher than that of osteoarthritis patients. Moreover, the above data have shown SphK
modulation through DMS significantly reduced the levels of pro-inflammatory
mediator synthesis in our cell-contact assays. In the murine CIA models,
intraperitoneal administration of DMS significantly inhibited disease severity and
reduced articular inflammation and joint destruction, and pro-inflammatory responses
both in vivo and in vitro.
The detailed pathways that drive cytokine release in RA synovium are still unclear but
it is well-established that T cells play a significant role by direct release of IL-17 or
via cell-contact with synovium macrophages (100, 101, 110, 174, 297, 298). DMS
was effective in suppressing T cell-monocyte interactions, an important pathway
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driving pro-inflammatory cytokine production in the synovium (110, 174). I have
demonstrated in a series of cell-contact experiments, employing either Jurkat/U937
cells or PB T cells and autologous monocytes derived from RA patients, that DMS
significantly reduced cell-contact induced pro-inflammatory TNF-, IL-1ß and IL-6,
and chemokine MCP-1 synthesis in a dose-dependent manner. More importantly,
MMP-9, a collagenase that plays a direct role in cartilage degradation and subsequent
bone erosion in RA (302), was significantly inhibited by the presence of DMS. This is
could be due to a direct blockade of MMP-9 synthesis, a direct interference with
monocytes/T cells interaction (180), or an indirect effect of TNF- and IL-1ß
suppression (138).
CIA represents an ideal opportunity to explore the diverse inflammatory effects on
SphK modulation in an inducible, autoimmune model. CIA has served as a
translational model in which the role of inflammatory cytokines in RA, particularly
TNF-, IL-1, and IL-17 were defined (99, 299). The above data have indicated that
DMS administration into CIA mice resulted in significantly reduced joint pathology
and subsequent pro-inflammatory responses. Activation of various plasma membrane
receptors of direct relevance in RA, such as the fMLP receptor (26), the C5a receptor
(27, 28), and TNF- receptor (29), leads to rapid increase in intracellular S1P level
via SphK stimulation. S1P can promote neutrophils, monocytes and lymphocyte
activation and migration (27-29, 48, 285, 286, 289, 290). The above data suggest that
SphK modulation via DMS may possess inhibitory action on inflammatory cell
infiltration into the joint, subsequent synovium hyperplasia and erosion as revealed by
histological examination. Such suppressive action of DMS on leukocyte migration is
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consistent with previous studies showing that SphK plays a role in chemotaxis of
human peripheral blood neutrophils and macrophages (27, 28, 290). Inhibition of
SphK may have a direct effect on cellular migratory machinery such as Ca2+
mobilisation and expression of adhesion molecules including VCAM-1 and E-selectin
(41). Finally, reduced S1P production after DMS treatment may also be directly
responsible for the reduced cell infiltration as S1P has been shown to be able to act as
a chemokine (46, 48, 306).
In addition, I have shown that blockade of SphK activity with DMS significantly
reduced the levels of CII-specific IgG1 and IgG2a antibodies in the serum of arthritic
mice. The current data indicate that DMS has an inhibitory action on the levels of
circulating S1P in serum of treated mice in dose-dependent manner as compared with
carrier controls. It is of interest that B cell lines derived from RA patients are uniquely
resistant to Fas-mediated apoptosis, in part due to over-activity of SphK1, and over
production of S1P, which can inhibit apoptosis and regulate lymphoid migratory
pathways (301). A follow-up study by the same group shows that the Fas death
signalling aberration in RA lymphoblastoid B cell lines is caused by extracellular S1P,
which triggers PI3K-dependent SphK over-activity through a Gi protein-coupled
receptor-mediated signalling cascade (308). In addition, FTY720-phosphate, which
binds to S1P receptors, caused the rapid disappearance of peritoneal B cells by
inhibiting both their emigration from parathymic lymph nodes, and reduced peritoneal
B cell-derived intestinal secretory IgA production (293). Together, this suggests S1P
may play an important role in regulating B-cell survival, trafficking and Ab
production.
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Blockade of SphK activity with DMS also significantly reduced serum levels of pro-
inflammatory IL-6, TNF-α, and IFN-γ, as well as in vitro production of these
cytokines in response to CII. These data suggest that the anti-inflammatory effect of
DMS is at least in part mediated through a suppressive action of antigen-specific T
cell responses, likely via the reduction in circulating S1P level.
More recently, fibroblast-like synoviocytes (FLS) were shown to express the S1P1,
S1P2, and S1P3 receptors (309). Moreover, exogenously applied S1P induces FLS
migration, secretion of inflammatory cytokines/chemokines, and protection from
apoptosis. The effects of S1P on FLS were further amplified by addition of TNF-α,
suggesting that the cytokine-rich environment of the inflamed synovium may
synergize with S1P signalling to exacerbate the clinical manifestations of RA. S1P has
also been shown to induce chemotaxis and regulates the migration of osteoclast
precursors in culture and in vivo (310). Cells with the properties of osteoclast
precursors express functional S1P1 receptors and exhibit positive chemotaxis along an
S1P gradient in vitro. Osteoclast/monocyte lineage-specific conditional S1P1
knockout mice showed osteoporotic changes due to increased osteoclast attachment to
the bone surface, as these osteoclast precursors are unable to recirculate from bone
tissues to systemic blood flow. Treatment with FTY720 ameliorate bone loss in a
murine model of postmenopausal osteoporosis by promoting the recirculation of
osteoclast precursor monocytes from the bone surface.
In conclusion, it was demonstrated in this chapter that synovial fluid of RA patients
exhibited higher concentration of S1P than their non-inflammatory OA counterparts,
and DMS suppressed cytokine and MMP-9 release by RA-derived PBMCs and
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human monocytic cell lines following cell contact-dependent interaction with
activated T lymphocytes. While testing such hypotheses reliably in pre-clinical
studies remains challenging, the potential clinical relevance of the above observations
is illustrated by DMS can effectively suppress murine CIA both in vivo and in vitro
via specific suppression of the pathologic pro-inflammatory and Th1 responses.
Therefore, it is conceivable that SphK modulation may play a beneficial role in the
treatment of inflammatory diseases such as RA.
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Chapter 5




As described in the previous chapters, Sphingosine kinase (SphK) and its product
sphingosine-1-phosphate (S1P) have important roles in various inflammatory
processes. Thus far, two mammalian SphKs, SphK1 and SphK2, have been identified
and characterised (10, 30, 32). SphK1 was found to be a critical regulator in TNF-
mediated IL-1 and IL-6 pro-inflammatory responses in human monocytes (29). In
RAW macrophages, TNF- induced PGE2 production can be inhibited by
downregulation of SphK1 via siRNA inhibition (312). SphK1 expression is increased
in human inflammatory bowel disease (IBD) colons. Importantly, in a murine model
of IBD, SphK1 deficient mice are protected from disease manifestations such as
weight loss, colon pathology, anemia, and leukocytosis, indicating the therapeutic
potential of SphK1/S1P modulation in the treatment of inflammatory diseases (95). In
contrast, SphK2 is required for the maintenance of T-helper cells homeostasis. CD4+
T cells from SphK2 deficient mice exhibit a hyper-activated phenotype with enhanced
proliferative and Th1 cytokine-secreting capacities, and promote IBD in SCID mice.
This is in part due to IL-2 induced abnormal accentuated STAT5 phosphorylation and
is independent of S1P (96).
Elevated SphK1, S1P, and S1P1 have been detected in RA synovium, and S1P
signalling via S1P1 was found to promote synoviocyte proliferation, cytokine-induced
COX-2 expression, and PGE2 production (264). Lymphoblastoid cell lines from
patients with RA were shown to be resistant to Fas-mediated cell death, in part due to
over-activity of SphK1 (301). In RA primary fibroblast-like synoviocytes (FLS), S1P
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receptors were shown to be essential for the FLS survival, migration and
inflammatory cytokine production (309). More recently, SphK2 was shown to be
strongly expressed in rheumatoid synovial fibroblasts (304). In contrast to SphK1
which is normally found in the cytosol, SphK2 expression was found in and around
the nuclei. Furthermore, SphK2 was responsible for FTY720-mediated apoptosis in
the synovial fibroblasts, suggesting that it may regulate the autonomous proliferation
of synovial fibroblasts.
In the previous chapter, it was shown that synovial fluid of RA patients exhibited
higher concentration of S1P than those with osteoarthritis. Furthermore, N,N-
dimethylsphingosine (DMS), a potent SphK inhibitor, significantly reduced
inflammatory mediators released by RA-derived peripheral blood (PB) monocytes
following cell contact-dependent interaction with activated T cells (313). In a murine
collagen-induced arthritis (CIA) model, intraperitoneal (i.p.) administration of DMS
significantly suppressed joint destruction and pro-inflammatory cytokine production
in vivo and in vitro (313). In the present chapter, I investigated if targeting SphK
activities, through downregulation of SphK1, or SphK2, may modulate the
development of CIA. Firstly, it was found that knocking down SphK1 with antisense
oligonucleotides can effectively reduced inflammatory mediators released by human
promyelocytic cells following in vitro cell contact-dependent interaction with
activated T cells. In the mouse CIA model, SphK1 downregulation via siRNA also
suppressed synovial inflammation, joint erosion, and pro-inflammatory cytokine
responses in vivo and in vitro where as SphK2 knockdown resulted in enhanced
disease severity. These data identify the distinct roles of SphK1 and SphK2 in
regulating the development of inflammatory arthritis.
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Results
5.1 Downregulation of SphK1 via specific antisense oligonucleotides reduce
Jurkat T cell contact-induced cytokine production via cognate interactions in
human promyelocytic cell line HL-60
In the previous chapter, I have demonstrated that PB T cells from RA and Jurkat T
cells, after activation by PHA/PMA, were capable of driving PB monocytes and,
U937 and HL-60 cells, to produce proinflammatory cytokines such as TNF- in a
cell-contact dependent manner (as discussed in chapter 4). I therefore investigated the
effect of knocking down SphK1 on the production of pro-inflammatory cytokines by
HL-60 in response to activated Jurkat T cells in a similar cell contact co-culture
system. Jurkat T cells were cultured with PHA and PMA, fixed with
paraformaldehyde and then co-cultured with human HL-60 promyelocytic cells, in the
presence of SphK1 or scrambled control antisense oligonucleotides. As expected,
activated T cells induced substantial production of TNF-, IL-1, and IL-6 by HL-60
cells. Such cytokine synthesis was markedly reduced when the HL-60 cells were
treated with SphK1 antisense oligonucleotides but not with scrambled control
(Fig.5.1).
To determine the specificity and level of SphK1 protein reduction, HL-60 cells were
harvested and lysed after 48 hours of SphK1 or scrambled control antisense treatment
as described in Materials and Methods section 2.6.1, and western blot analysis was
performed to study SphK1 modulation. Fig. 5.2A, B shows SphK1 protein expression
in the HL-60 cell lysates was effectively downregulated by SphK1 antisense treatment,
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whereas scrambled control remains unaffected. Using densitometry analysis, it was
observed that SphK1 expression was reduced by over 55% in cells treated with the
specific SphK1 antisense, with respect to loading control GAPDH expression.
Together, these data demonstrated that SphK1 is the isoform responsible for
modulating pro-inflammatory cytokines production in the in vitro cell-contact model.
Figure 5.1 SphK1 antisense oligonucleotides inhibit cytokine production from HL-60
promyelocytic cells in vitro
Paraformaldehyde-fixed PMA/PHA stimulated (Ts) or medium control (Tc) Jurkat T
cells were co-cultured with HL-60 cells either in medium alone or in the presence of
SphK1 or scrambled control antisense. Activated Jurkat T cells induced IL-1, IL-6,
and TNF- production by HL-60 cells in a cell contact-dependent fashion and was
significantly inhibited by SphK1 antisense but not the scrambled control antisense.
Data are mean ± SEM of triplicate cultures and are representative of three similar
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Figure 5.2 Downregulation of SphK1 protein expression in HL-60 cells treated with
antisense oligonucleotides
HL-60 cell were lysed after 48 hours of antisense treatment and SphK1 protein
expression was examined by western blot as described in section 2.6.2. SphK1 (lane
1), and Scrambled control (lane 2), are represented. SphK1 protein expression was
effectively reduced by SphK1 antisense, where as Scrambled control remains
unaffected (A and B). SphK1 expression was reduced by over 55% as determined by
densitometry analysis (% GAPDH expression). Equal loading of proteins was
confirmed using GAPDH as an internal control. Blot shown is a representative from
three independent experiments with similar results.
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5.2 SphK1, but not SphK2 downregulation suppressed development of CIA
The effects of SphK1 and SphK2 downregulation were further investigated in the CIA
model in DBA/1 mice, a surrogate model of human RA. DBA/1 mice were
immunised with bovine type II collagen (CII)/CFA as described in previous chapter.
Mice began to show clinical sign of arthritis on day 30 after immunisation. DBA/1
mice were given intraperitoneal 200 µg/kg of siRNA against either SphK1, or SphK2,
or scrambled siRNA as control on day 20-22, and then once every 2 days until day 45.
The severity of arthritis was measured by sequential estimation of the articular index,
which is a graded score given to each paw according to the severity of arthritis, and
was compared for involved animals within each group. SphK1 siRNA significantly
suppressed the incidence and severity of development of CIA when compared to
control mice that received scrambled siRNA (p < 0.05, Fig. 5.3A-C) whereas SphK2
siRNA failed to suppress the severity of developing CIA (Fig. 5.3), suggesting such
inhibition is dependent of SphK1 rather than SphK2. Furthermore, mice that received
SphK2 siRNA developed severe inflammatory, polyarticular disease by day 33 as
indicated by mean articular index (Fig. 5.3B) whereas the incidence of arthritis was
comparable to mice that received scrambled control.
The siRNA dose chosen is consistent with the previous in vivo murine studies
(typically 4-8 g/animal) where it was observed that SphK1 protein expression in
lysates of PBMC, spleen, lung and liver was effectively downregulated by
administration of SphK1 siRNA (94, 307). To determine the specificity and levels of
SphK1 and SphK2 protein reduction, spleen cells were isolated from mice (n = 5) 24
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hours after the last SphK1 or SphK2 siRNA treatment as described above and western
blot analysis was performed to study SphK1/2 modulation. Fig. 5.4A-C shows SphK1
protein expression in the spleen lysates was effectively downregulated by SphK1
siRNA treatment, whereas SphK2 remains unaffected, suggesting the reduction of
CIA disease activity was specific and is dependent of SphK1 rather than SphK2.
Similarly, protein levels of SphK2 but not SphK1 was effectively reduced in SphK2
siRNA-recipients. Both SphK1 and SphK2 expression was reduced by over 55% as
determined by densitometry analysis.
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Figure 5.3 SphK1 but not SphK2 siRNA treatment attenuated the progression of
murine CIA
Collagen-primed DBA/1 mice were injected i.p. with 200 g/kg (equivalent to 5
g/animal) of siRNA against SphK1 (n = 12 mice/group), SphK2 (n = 7 mice/group),
or with scrambled control (n = 12 mice/group) from days 20-22 and then once every 2
days until day 45. Mice were monitored for disease progression as indicated by (A)
incidence (%), (B) mean articular index, and (C) mean number of arthritic paws.
SphK1 siRNA-treated mice developed arthritis of significantly lower incidence and
severity when compared with mice received scrambled siRNA whereas SphK2 siRNA
recipients developed exacerbated disease than did control animals. Data are expressed
as mean ± SEM. *, p<0.05 vs control by Mann-Whitney U test for mean anrticular
index and mean paw thickness. *, p<0.05 vs control by chi-square contingency
analysis for % incidence.
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Figure 5.4 Downregulation of SphK1 and SphK2 protein expression in mice treated
with siRNA
Spleen cell lysates were harvest 24 h after the last siRNA treatment (day 46) and
SphK1/2 protein expression was examined by western blot as described in section
2.6.2. Scrambled control siRNA(lane 1), SphK1 siRNA (lane 2), and SphK2
siRNA(lane 3) are represented. SphK1 protein expression was effectively blocked by
SphK1 siRNA, where as SphK2 remains unaffected (A and B). Similarly, SphK2 but
not SphK1 protein expression was effectively reduced in SphK2 siRNA recipients (A
and C). Both SphK1 and SphK2 expression was reduced by over 55% as determined
by densitometry analysis (% GAPDH expression). Equal loading of proteins was
confirmed using GAPDH as an internal control. Blot and corresponding densitometry
results are representatives from three independent experiments with similar results.
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5.3 Treatment with SphK1, but not SphK2 siRNA, reduced inflammatory
infiltrate into the synovium and articular destruction
To determine whether SphK siRNA administration modified articular destruction,
cartilage and bone integrity were evaluated histologically. Adjacent cartilage and
bone erosion, synovial hyperplasia, and inflammatory infiltration into the joint
compartment were clearly evident in the scrambled siRNA controls (Fig. 5.5A). Each
of these parameters was markedly suppressed in mice received SphK1 siRNA
whereas SphK2 siRNA recipients exhibit joint destruction comparable to those seen
in scrambled control mice (Fig. 5.5A-D). Together, these data clearly indicate that
downregulation of SphK1 but not SphK2 potently suppressed the development of CIA
and such activity can prevent the progression of articular damage.
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Figure 5.5 SphK1 siRNA administration significantly reduced articular inflammation
and destruction
H&E sections prepared from hind paws (n = 6/group) obtained at day 46 were scored
for the presence of cartilage/bone erosion, synovial hyperplasia, and inflammatory
infiltration. SphK1 siRNA-treated mice developed significantly lower pathological
changes than mice received either SphK2, or scrambled siRNA (A). A representative
H&E section from each group of mice is shown. SphK1 siRNA-treated mice showed
reduced histological evidence of destruction (B). Profound cartilage and bone erosion,
hyperplasia, and cellular infiltration were observed in the SphK2 (C) and scrambled
siRNA-treated mice (D). Data are means ± SEM. *, p < 0.05 vs scrambled control by
Mann-Whitney U test.
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5.4 Effect of SphK siRNA treatment on serum cytokines and S1P levels
Based on recent data from CD4+ T cells of SphK2 deficient mice, it was suggested
that SphK2 may play an important role in regulating T cell responses and is
independent of S1P (96). Therefore, a potential mechanism by which SphK1/2 siRNA
downregulation could modify CIA pathology is by altering pro-inflammatory
cytokine profile in vivo. The effect of siRNA treatment before the onset of clinical
arthritis on day 27 was studied. Serum cytokines including IL-6, IL-10, TNF-, and
IFN- were all below the ELISA detection limits (<10 pg/ml), presumably as day 27
precedes the acute phase of CIA where anti-CII responses are still under development.
Next, serum cytokine concentrations from arthritic mice with established disease at
the end of the treatment period (day 46) were investigated. High levels of IL-6, TNF-
, and IFN- were detected in scrambled controls and SphK2 siRNA recipients. These
were present at significantly (p<0.05) reduced levels in mice treated with SphK1
siRNA (Fig. 5.6 A-C). Moreover, serum IL-10 levels were significantly elevated in
SphK1 siRNA recipients (Fig. 5.6D), suggesting that systemic inflammatory
responses were modified.
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Figure 5.6 Serum proinflammatory cytokines in siRNA-treated mice
Arthritic DBA/1 mice treated with i.p. 200 g/kg SphK1, SphK2, or scrambled
control siRNA were sacrificed on day 46, and serum was collected from five mice in
each group. Levels of IL-6 (A), TNF- (B), IFN- (C), and IL-10 (D) were determined
by ELISA of individual samples. Data are means ± SEM. *, p < 0.05 vs scrambled
control by Student’s t test.
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S1P level is increased in the disease tissues in inflammatory conditions such as RA
and IBD, which may modify immune cell trafficking (95, 264, 309). Therefore it was
important to determine the level of S1P modulation achieved by targeting SphK1 or
SphK2 with specific siRNA. No evidence of significant changes in serum S1P level
was observed during early stage of siRNA treatment before the onset of clinical
arthritis on day 27 (naïve mice 2.0 M ± 0.3, scrambled control 2.5 M ± 0.4, SphK1
2.2 M ± 0.4, SphK2 2.7 M ± 0.6, mean ± SEM, n = 5 mice/group). However, in
arthritic mice with established disease at the end of the treatment period (day 46), a
significant reduction in serum S1P level was observed in SphK1 but not SphK2
siRNA recipients (Fig. 5.7), suggesting that S1P responses were indeed modified by
direct targeting of SphK1 via siRNA. Finally, significant increases in serum S1P level
was observed in all 3 groups of siRNA-treated arthritic mice compared with naïve
age-matched controls (p < 0.05).
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Figure 5.7 Serum S1P level in siRNA-treated mice
Sera were obtained from siRNA-treated mice on day 46 with established disease or
age-matched naïve controls and S1P was measured by ELISA. A significant reduction
in serum S1P level was observed in SphK1 but not SphK2 siRNA recipients.
Significant increased in serum S1P level was observed in all 3 groups of siRNA-
treated arthritic mice compared with naïve controls (p < 0.05). Data are individual
measurements (n = 5/group) and expressed as mean ± SEM, *, p < 0.05 vs scrambled
control by Student’s t test.
137
5.5 SphK1-siRNA suppresses collagen-specific pro-inflammatory immune
responses in vitro
Next, the mechanisms whereby inhibitory effects on systemic inflammatory responses
could be achieved were investigated. CIA is associated with a pro-inflammatory
immune response, rendering it an excellent model to explore the effect of SphK1/2
downregulation upon functional T cell response in vivo. CII-specific immune
responses were examined in vitro in pooled draining lymph nodes obtained at day 27
before onset of disease. Cells from SphK1 siRNA-treated mice produced significantly
less CII-induced IFN-, TNF- and IL-6 compared with cells from scrambled control
animals (Fig. 5.8A-C) whereas significantly increased in CII-induced production of
IFN- and TNF- was noted in SphK2 siRNA recipients (Fig. 5.8A, B). Neither IL-10
production nor proliferation was modified (Fig. 5.8D, E). Next, CII-specific immune
responses were examined in vitro in pooled draining lymph nodes obtained at day 46
from mice with established disease. Cells from SphK1 siRNA-treated mice produced
significantly less spontaneous and CII-induced IFN- compared with cells from
scrambled control animals (Fig. 5.9A). CII-induced production of TNF- IL-6, and
proliferation was also significantly reduced in SphK1 siRNA treated mice, whereas
IL-10 production was slightly elevated although not statistically significant (Fig.
5.9B-E). In contrast, CII-induced production of IFN- and TNF- was significantly
increased in SphK2 siRNA recipients compared to scrambled controls (Fig. 5.9A, B).
Immune modulation by SphK1 and SphK2 siRNA in vivo was antigen-specific since
Con A-induced proliferation and production of IFN- and TNF- in parallel cultures
was not affected. Together, these data clearly indicate that downregulation of SphK1
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via prophylactic siRNA treatment may modify the development of pro-inflammatory
and Th1 responses.
Figure 5.8 Downregulation of SphK1 decreases in vitro CII-specific pro-
inflammatory cytokine production
Draining lymph node cells (n = 5 mice/group) were harvested from mice on day 27
before onset of disease and cultured with CII (50 g/ml) for up to 96 hours. Cytokine
concentrations in the culture supernatant (72 hours for IL-6, and TNF-; 96 hours for
IL-10 and IFN-) were determined by ELISA. Significant suppression of IFN- (A),
TNF- (B), and IL-6 (C) production was observed in lymph node cultures removed
from SphK1 siRNA-treated mice compared with scrambled controls whereas IFN-
and TNF- was enhanced in SphK2 siRNA recipients (A and B). T cell proliferation
was assayed by Alamar Blue at 96 hours (E). Data are mean ± SD of triplicate
cultures, *, p<0.05 vs scrambled control by Student’s t test.
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Figure 5.9 SphK1 siRNA-treatment reduces in vitro anti-CII responses in mice with
established disease
Draining lymph node cells (n = 5 mice/group) were harvested from arthritic animals
on day 46 and cultured either with medium alone or CII (50 g/ml) for up to 96 hours.
Significant suppression of IFN- (A), TNF- (B), and IL-6 (C) production was
observed in lymph node cultures removed from SphK1 siRNA-treated mice compared
with scrambled controls whereas TNF- and IFN- was enhanced in SphK2 siRNA
recipients. CII-induced IL-10 production was significantly higher in mice received
siRNA against SphK1 than SphK2 animals (D). T cell proliferation was assayed by
Alamar Blue at 96 hours (E). Data are mean ± SD of triplicate cultures, *, p<0.05 vs
scrambled control by Student’s t test.
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5.6 Anti-collagen antibodies (Ab) production in vivo
Finally, anti-collagen Ab production in these mice was evaluated. On day 27, CII-
specific IgG1 and IgG2a levels were analysed by ELISA and found to be low and
similar in all three groups of mice. However, by day 46, CII-specific IgG2a Abs,
which are typically produced during a Th1 response, were found to be reduced in
SphK1 siRNA-treated mice compared with scrambled controls and SphK2 siRNA-
recipients (Fig. 5.10A). CII-specific IgG1 levels were not significantly different (Fig.
5.10B). This data suggest that SphK1 isoform may play a role in modulating antigen-




Figure 5.10 Serum anti-CII IgG2a and IgG1 levels in siRNA-treated mice
Anti-CII IgG2a (A) and IgG1 (B) Ab levels were measured on day 46 by ELISA. Data
are expressed as mean absorbance (OD630) ± SEM of individual serum
measurements (n = 5 mice/group). Data are means ± SEM. *, p < 0.05 vs scrambled
control by Student’s t test.
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Discussion
Although a critical role of the interaction between SphK and S1P in immune cell
function has been identified (296, 314), the precise contribution of SphK1 and SphK2
to the development of autoimmune diseases such as RA is as yet poorly understood.
In the previous chapter, it was shown that the synovial fluid of RA patients displayed
higher concentration of S1P than did those with osteoarthritis (313). SphK modulation
either through DMS, or SKI2, significantly reduced the levels of TNF-, IL-1, IL-6,
MCP-1 and MMP-9 synthesis in cell-contact assays. Administration of DMS reduced
clinically detectable inflammatory arthritis in DBA/1 mice (313). The present chapter
now compares the role of SphK1 with that of SphK2, and documents the distinct roles
of these two isoenzymes in regulating inflammatory arthritis. Cell-cell contact is an
important mechanism involved in driving cytokine production in the RA synovium.
The current data indicate that SphK1 downregulation with antisense oligonucleotides
significantly reduced the levels of TNF-, IL-1, and IL-6 in cell-contact assays,
rendering SphK1 the isoform responsible for contact-dependent cytokine production.
SphK1 can promote CIA, as downregulation of its expression through siRNA
significantly suppressed the development and severity of CIA, as well as pro-
inflammatory responses in vivo and in vitro in CII-immunised mice. In contrast,
downregulation of SphK2 via siRNA therapy resulted in exacerbation of disease and
inflammatory changes.
SphK/S1P exerts pleiotropic effects on a variety of leukocyte subsets such as the T
and B cells, macrophages, monocytes, and neutrophils (296, 314). Moreover, studies
have shown that SphK/S1P participates in several inflammatory responses such as
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leukocyte chemotaxis, and cytokine production and blockade of SphK activity
suppresses such responses (27-29, 94, 290, 307, 312, 313). SphK1 and S1P were also
implicated in various autoimmune conditions such as RA (264, 301, 309), primary
Sjögren's (305), and IBD (95). Elevated SphK1, S1P and S1P1 levels have been
detected in RA synovium, and S1P signalling via S1P1 was found to promote
synoviocyte proliferation, inflammatory cytokine-induced COX-2 expression and
PGE2 production (264, 301). In human RA primary FLS, S1P1 was shown to be the
essential signal for survival, S1P1/S1P3 stimulated FLS migration whereas activation
of S1P2/S1P3 enhanced IL-6 and IL-8 secretion. In addition, TNF-α was shown to
promote FLS S1P3 expression and S1P-mediated IL-8 secretion (309). Thus, the
above pathways are likely to contribute to the immunomodulatory effects of SphK1 in
inflammatory arthritis.
The data presented in this chapter indicate that SphK1 downregulation via siRNA
might suppress synovitis as revealed by histological examination. Several
mechanisms can be put forward to explain such observation. The suppressive action
on leukocyte migration is consistent with previous studies showing that SphK1 play a
role in chemotaxis of human peripheral blood neutrophils and macrophages (27, 28).
Inhibition of SphK1 may have a direct effect of cellular migratory machinery such as
Ca2+ mobilisation and expression of adhesion molecules including ICAM-1, VCAM-1
and E-selectin (28, 95, 315). In addition, significant reduction of serum S1P level in
SphK1 siRNA-treated mice may also be a contributing factor for the inhibition in
synovitis, as S1P has been shown to act as a chemotactic signal (46, 47, 309). It is of
interest that serum S1P level was also lowered, but not as extensively, in SphK2-
siRNA recipients.
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Downregulation of SphK1 significantly reduced serum levels of CII-specific IgG2a.
The effect on Ab production may play a role in SphK1 siRNA-mediated amelioration
of CIA as B cell-mediated pathology is of critical importance in RA (316). B cell lines
derived from RA patients are uniquely resistant to Fas-mediated apoptosis, in part due
to over-activity of SphK1, and over production of S1P, which can inhibit apoptosis
and regulate lymphoid migratory pathways (301). In mice, FTY720-phosphate, which
binds to S1P receptors, caused the rapid disappearance of peritoneal B cells and
reduced intestinal secretory IgA production. This suggests S1P may play an important
role in regulating B-cell survival, trafficking and Ab production (293).
SphK1 was found to be a critical regulator in TNF- mediated IL-1 and IL-6
proinflammatory responses in human monocytes (29). In RAW macrophages, TNF-
induced PGE2 production can be inhibited by downregulation of SphK1 via siRNA
knockdown (312). SphK1 expression is increased in human IBD colons, and SphK1
deficient mice are protected from IBD pathology (95). These are in contrast to data
generated from models of thioglycollate-induced peritonitis and CIA, where SphK1
knockout mice exhibited normal acute and chronic inflammatory responses (317). It is
possible that mice lacking the SphK1 gene during embryonic development may be
adapted not to rely on this pathway for inflammatory responses postnatally. This is
supported by the fact that both SphK1 and SphK2 single knockout mice develop and
reproduce normally, whereas complete elimination of S1P in the double knockout is
embryonically lethal (318). This observation suggests that each isoenzyme of SphK
may at least partially compensate for the lack of the other. Thus, blockade of SphK in
normal animals may lead to modification of inflammatory responses, and it has been
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recently validated that SphK1 indeed plays a critical role in regulating acute
inflammation (94).
In contrast, the role of SphK2 in inflammation remains poorly defined. The data
presented in this chapter suggest that downregulation of SphK2 resulted in increased
disease activity and pro-inflammatory responses. I have found that at day 27 prior to
the development of arthritis, SphK2-siRNA treatment can potentially polarise in vitro
T cell anti-CII response into a proinflammatory manner and is unlikely associated
with changes in the concentration of serum S1P. Others have demonstrated similar
findings, T cells from SphK2 knockout mice exhibit hyper-activated phenotype with
enhanced proliferative and Th1 cytokine-secreting capacities, and promote IBD
pathology in SCID mice, suggesting SphK2 may play an important role in
maintaining T cell homeostasis (96). In addition, a recent study found that SphK2 is
highly expressed in rheumatoid synovial fibroblasts, and that it is responsible for
FTY720-mediated apoptosis in these cells (304). Hence, downregulation of SphK2
could potentially alter Th1/2 cell balance, synoviocytes survival, and disease outcome,
and future studies will be required to address this possibility.
In conclusion, I have demonstrated the distinct roles of SphK1 and SphK2 in
regulating inflammatory arthritis. Downregulation of SphK1 via siRNA significantly
attenuated the development of CIA and pro-inflammatory responses when
administered prophylacticly. SphK1 downregulation also inhibited T cell contact-
dependent pro-inflammatory cytokine production by the monocytes in vitro. In
contrast, SphK2 modulation can promote CII-induced inflammatory arthritis. The data
presented in this chapter clearly shows that such anti- and pro-inflammatory potential
146
of SphK1/2 modulation may alter the outcome in RA synovitis and in other
autoimmune diseases such as IBD in which similar pathways are implicated. Defining
the functional dichotomy between the two isoenzymes is thus of paramount
importance. These findings raise the possibility that drugs specifically target SphK1






Research has been on-going in attempt to discover new therapies for asthma in face of
the increasing prevalence of the disease in many developed nations. Allergic asthma
is a heterogeneous chronic lung disease characterised by airway hyperresponsiveness
(AHR), inflammatory infiltrates in the bronchial walls containing eosinophils, and
elevated serum IgE levels. Lung biopsies of asthmatic patients have revealed
pulmonary infiltration of lymphocytes, particularly of the T-helper 2 (Th2) type,
macrophages, mast cells and eosinophils. Together with the resident airway cells,
these cells interact with one another to initiate and perpetuate allergic airway
inflammation via the production of various inflammatory mediators (206). The
conventional therapy for allergic asthma is corticosteroids. However, it is not without
side effects and there remains a subset of patients who respond poorly to such
treatment.
Recent developments in sphingosine kinase (SphK)/sphingosine-1-phosphate (S1P)
research may provide a potential therapeutic breakthrough. The regulation of SphKs
and their product, S1P, are becoming a topic of intense research in immunology.
SphKs and S1P have been demonstrated to play critical roles in various inflammatory
responses and diseases, and modulation of SphK activity and maintaining S1P
homeostasis are important for preventing unwanted immune responses. S1P promotes
monocytes and lymphocyte activation and migration (8, 48, 285, 286), and mast cells
degranulation and chemotaxis (23, 25, 83). In a rat-paw model, local administration of
S1P causes inflammation coupled with eosinophil recruitment, which can be inhibited
by anti-CCR3 antibodies (Ab) (50). Moreover, elevated levels of S1P in
bronchoalveolar lavage (BAL) fluid were recovered from allergic asthma patients
after ragweed antigen (Ag)-challenge and may play a role in both acute
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bronchoconstriction and airway remodelling through its direct action on airway
smooth muscle cells (263, 287). In a murine model of asthma, S1P causes a dose-
dependent contraction of bronchi and triggers AHR in OVA-sensitised mice, and is
coupled to an enhanced expression of SphK1, SphK2, and S1P2 and SIP3 receptors
(288). In addition, SIP has been proposed to be a key regulator of Th2 lymphocyte
trafficking in an OVA-induced food allergy model in mice (289).
In the current study, the effects of SphK blockade in murine OVA-induced allergic
asthma model were investigated. The data demonstrate that sphingosine kinase
inhibitor, N,N-dimethylsphingosine (DMS), and SphK1 siRNA have inhibitory
actions on inflammatory cells infiltration into the lungs, as revealed by histological
examinations, and a significant drop in total cells and eosinophil counts in BAL fluids.
This suppressive action of DMS/SphK1 siRNA on leukocyte migration is consistent
with the role of S1P in chemotaxis of various immune cells (27, 28, 50, 290), and
could also be partially due to a direct effect on cellular migratory machinery such as
Ca2+ mobilisation and expression of adhesion molecules including VCAM-1 and E-
selectin (41). Finally, an indirect effect mediated through the suppression of
chemokine production is also possible as reduced eotaxin BAL levels were observed
in mice receiving DMS and SphK1 siRNA.
The present data show that the anti-inflammatory effect of SphK1 blockade is at least
in part mediated through a suppressive action on T lymphocytes, as OVA-specific cell
proliferation, IL-4 and IL-5 production was reduced in thoracic lymph node cultures
from DMS and SphK1 siRNA-treated mice. A reduction in BAL fluid IL-4, IL-5 and
eotaxin levels was also observed in these mice.
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In addition, the anti-inflammatory effects of SphK blockade may extend to resident
airway smooth muscle (ASM) cells, as DMS administration significantly suppressed
OVA-induced AHR to methacholine in a dose-dependent manner. S1P has been
identified as an important factor in orchestrating both the acute asthmatic
bronchoconstriction and the chronic features of airway remodelling (263, 287, 288).
Thus, the suppression of AHR by DMS could in part due to the direct inhibition of
ASM contraction. The observed alleviation of AHR may be also associated with the
reduced tissue eosinophilia and Th2 cytokine levels via SphK pathway inhibition.
IgE mediated mast cell activation and degranulation is a hallmark of allergic
inflammation. I found that serum levels of OVA-specific IgE were reduced by SphK1
siRNA, suggesting SphK/S1P may play an important role in regulating B-cell
antibody production. Furthermore, these data was reinforced by recent studies by
Nishiuma et al. and Roviezzo et al. Using a similar OVA-induced asthma mouse
model (294), Nishiuma found that DMS or SK-I [SK-I; 2-(p-hydroxyanilino)-4-(p-
chlorophenyl) thiazole] inhalation resulted in a decrease in S1P level in BAL fluid,
accompanied by decreased eosinophil infiltration and peroxidase activity. OVA-
induced increase in IL-5, IL-13, and eotaxin levels in the BAL fluid were significantly
suppressed by DMS pretreatment. Moreover, bronchial hyperresponsiveness to
inhaled methacholine and goblet cell hyperplasia were improved by SphK inhibitors.
Roviezzo et al. (295) demonstrated in Balb/c mice that S1P given subcutaneously
caused a specific and dose dependent increase in cholinergic reactivity of bronchial
tissues and whole lungs resistance in vitro. Lungs isolated from S1P-treated mice
displayed an increase in mast cell number and IL-4, IL-13 and IL-17 mRNAs. Taken
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together, these findings suggest SphK pathway may represent a novel target in the
treatment of asthma.
In a similar fashion, neither the initiating events nor the perpetuating factors in the
pathogenesis of RA are clearly understood in spite of many years of intensive
research. Most of the current knowledge of the inflammatory process and cellular
infiltrate in the rheumatoid joint comes from the study of synovium in established,
rather than early, disease. T cells, mainly of the CD4 memory type (109) are activated
in the acute phase of the disease and persist in the synovium throughout the disease
course. Mature plasma cells are also found abundantly in the RA synovium (111, 114).
These lymphocytes, together with neutrophils, mast cells, and the resident synovial
macrophages (127) and fibroblasts (133) interact with one another, via soluble factors
cross-talk (99) and direct cell-to-cell contact (110), forming a self-sustaining network
that generates large amounts of proinflammatory mediators that perpetuate and
exacerbate the disease.
To date, the gold standard for treating RA is the disease modifying anti-arthritic drugs
(DMARDs), with methotrexate being the most widely used DMARD for RA (135-
137), although the clinical success of anti-TNF-α therapy suggests that targeting the
cytokine network can be of immense benefit. The cytokine network is vast and
complicated, with each cytokine linked to another in distinct and/or overlapping
manners. Hence, targeting one specific cytokine may not be enough to efficiently
control, much less ameliorate the disease in the long term. The non-respondents to
anti-TNF-α therapy and the on-going research efforts targeting at signature
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inflammatory signalling pathways such as NF-κB (319) is evidence that more needs to
be done than single cytokine targeting.
Interestingly, SphK/S1P appears to play a role in modulating RA pathogenesis as well.
Activation of various plasma membrane receptors of direct relevance in RA, such as
the fMLP receptor (26), the C5a receptor (27, 28), and TNF- receptor (29), leads to
rapid increase in intracellular S1P level via SphK stimulation. S1P can promote
neutrophils, monocytes and lymphocyte activation and migration (27, 28, 48, 290).
Moreover, elevated SphK1, S1P, and S1P1 receptors have been detected in RA
synovium, and S1P signalling via S1P1 was found to promote synoviocyte
proliferation, cytokine-induced COX-2 expression, and PGE2 production (264). Over
-activity of SphK1 was found in lymphoblastoid cell lines from patients with RA,
rendering them resistant to Fas-mediated cell death (301). In RA primary fibroblast-
like synoviocytes (FLS), S1P1 was shown to be essential for the survival of FLS,
S1P1/S1P3 for FLS migration, and activation of S1P2/S1P3 promotes release of
proinflammatory cytokines including IL-6, IL-8, and TNF-α (309).
Collagen-induced arthritis (CIA) represents an ideal translational model to explore the
diverse inflammatory effects on SphK modulation in an inducible, autoimmune model.
The current data indicate that DMS or SphK1 siRNA administration into CIA mice
resulted in significantly reduced joint pathology and subsequent pro-inflammatory
responses. This suggests that SphK modulation may possess inhibitory action on
inflammatory cells infiltration into the joint, subsequent synovium hyperplasia and
erosion as revealed by histological examination. Such suppressive action of DMS and
SphK1 siRNA on leukocyte migration, as discussed above, may be due to direct
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effects on cellular migratory machinery such as Ca2+ mobilisation and expression of
adhesion molecules including VCAM-1 and E-selectin (41). Finally, reduced S1P
production in the serum of the mice after DMS and SphK1 siRNA treatment may also
be responsible for the reduced cell infiltration as S1P has been shown to be able to act
as a chemokine (46, 48). I also demonstrated that blockade of SphK activity
significantly reduced the levels of collagen-specific IgGa and IgG2a antibodies in the
serum of arthritic mice. This might partially be attributed to the effect of S1P on
regulating B-cell survival (301) and Ab production (293). Blockade of SphK activity
with DMS and SphK1 siRNA also significantly reduced serum levels of pro-
inflammatory IL-6, TNF-α, and IFN-γ, as well as in vitro production of these pro-
inflammatory cytokines in response to collagen. These data suggest that the anti-
inflammatory effect of DMS is at least in part mediated through a suppressive action
of antigen-specific T cell responses, likely via the reduction in circulating S1P level.
Effects of SphK blockade may extend to the osteoclasts as well. S1P has also been
shown to induce chemotaxis and regulates the migration of osteoclast precursors in
culture and in vivo (310). Cells with the properties of osteoclast precursors express
functional S1P1 receptors and exhibit positive chemotaxis along an S1P gradient in
vitro. Osteoclast/monocyte lineage-specific conditional S1P1 knockout mice showed
osteoporotic changes due to increased osteoclast attachment to the bone surface, and
treatment with FTY720 relieved ovariectomy-induced osteoporosis in mice by
reducing the number of mature osteoclasts attached to the bone surface. Collectively,
these data indicate that SphK1 modulation may play a beneficial role in the treatment
of inflammatory diseases such as RA.
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Taken together, SphK1 pathway is activated and appears to play a similar pro-
inflammatory role in both asthma and inflammatory arthritis mice models. More
fascinating is the fact that blockade of SphK1 activity reduces antigen-specific
inflammatory responses in both models. Thus, targeting SphK1 can be potentially
beneficial to treating an autoimmune disease like RA or an allergic disease like
asthma, and yet does not compromise global immunity.
This current study also provides a deeper insight into the role of each individual SphK
isoforms, namely SphK1 versus SphK2. Studies have been done in murine model of
inflammatory bowel disease (IBD) which suggested the distinct roles of SphK1 versus
SphK2 in the disease pathogenesis. SphK1 deficient mice are protected from disease
manifestations such as weight loss, colon pathology, anemia, and leukocytosis,
indicating the therapeutic potential of SphK1/S1P modulation in the treatment of
inflammatory diseases (95). In contrast, SphK2 is required for the maintenance of Th
cells homeostasis. CD4+ T cells from SphK2 deficient mice exhibit a hyper-activated
phenotype with enhanced proliferative and Th1 cytokine-secreting capacities, and
promote IBD in SCID mice (96). Furthermore, recent findings, that SphK2 is highly
expressed in rheumatoid synovial fibroblasts and is responsible for FTY720-mediated
apoptosis in these cells (304), reveal the tip of the iceberg, suggesting that SphK2
might be playing a protective role in RA.
In the CIA model, I found that downregulation of SphK2 resulted in increased disease
activity and pro-inflammatory responses. SphK2 siRNA-treated mice exhibited
increased joint pathology as compared to control and SphK1 siRNA treatment groups.
These mice were also associated with higher serum levels of pro-inflammatory IL-6,
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TNF-α and IFN-γ, and higher production of such cytokines in response to collagen in
vitro. In addition, I have found that at day 27 prior to the development of arthritis,
SphK2-siRNA treatment can potentially polarised in vitro T cell anti-collagen
response into a proinflammatory manner and is unlikely associated with changes in
the concentration of serum S1P.
The pro-inflammatory effects of the product of SphKs, S1P, and its receptors have
been highly researched on and documented. However, it is interesting that the product
of both isoenzymes, S1P, is identical, despite seemingly playing opposing roles in
various inflammatory diseases. This contradiction suggests that localisation of the
enzymes and S1P, for instance in the cytosol versus in the nucleus, may be important
in determining their divergent roles. It is also interesting to note that, unlike SphK1
knockdown, S1P level was not significantly disturbed when SphK2 was knockdown
by siRNA. This reiterates the fact that SphK1 enzymatic activity is higher, and could
also suggest that SphK1 is generally more abundantly expressed/highly activated in
the disease, allowing it to eclipse that of SphK2 and thus drives disease pathogenesis.
It is also tempting to propose that the enzymes may possess other functions that
discriminate between them, besides the production of S1P. For instance, it has been
proposed that Sphk2 may play a role in the regulation of activities that modulate
STAT5 phosphorylation independent of S1P (96). Furthermore, it has been
demonstrated that Erk1/2 MAPK pathway (320, 321), NF-κb pathway (29) and PI3K
pathway (308) crosstalk with the SphK pathways. Thus, it is plausible that SphK1
and/or 2 may also play a role in activating other signalling pathways, which may
either drive an overall pro-inflammatory or anti-inflammatory response.
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Therefore, selective targeting and/or dual-targeting of the two SphK isoforms might
be required to effectively modulate the sphingolipid metabolic pathway in such a way
that it becomes therapeutic in chronic inflammatory diseases such as asthma and RA.
157
Conclusion
The present study investigated the role of SphK in two chronic models of
inflammatory diseases, namely Allergic Asthma and Rheumatoid Arthritis. The
conclusions are as follows:
Blockade of SphK1 was effective in attenuating the development and severity of
collagen-induced arthritis in the mouse. This is mediated through various mechanisms,
including reduction of inflammatory infiltrates into the joint, reduction of serum pro-
inflammatory cytokine levels, and suppression of collagen-specific T and B
lymphocyte immune responses. These effects are likely to be partially a result of the
reduction in circulating S1P level. The SphK1 isoform plays a role in T lymphocyte
contact-dependent pro-inflammatory cytokines production by monocytes derived
from RA patients. As direct cell-cell contact is a critical mechanism in driving
cytokine production in the RA synovium, these data indicate that the anti-
inflammatory effects of SphK1 blockade may be in part due to its role in cell-contact
driven cytokine production. On the other hand, blockade of SphK2 exacerbated the
disease and proinflammatory responses, independent of the circulating S1P level.
The SphK1 isoform was also involved in the pathogenesis of OVA-induced allergic
asthma in the mouse. Blockade of SphK1 was effective in alleviating the disease
severity. This is also mediated through a reduction in pro-inflammatory infiltrates into
the lungs, reduction in BAL cytokine and chemokine levels, and suppression of OVA-
specific T and B cell responses. In addition, a direct effect on lung function was
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observed as DMS attenuated AHR in response to methacholine challenge, suggesting
that SphK may play a role in modulating airway smooth muscle cells function.
Together, these data indicate the distinct roles of SphK1 and SphK2 in chronic
inflammatory diseases and raise the possibility that drugs specifically target SphK1




Key areas of interest are the following:
 Therapeutic effects of SphK1 blockade in inflammatory arthritis –
administering the inhibitor or siRNA after clinical onset of the disease or at
the peak of the disease will provide a better indication of the clinical potential
of SphK1 blockade in RA.
 Role of SphK2 in asthma pathogenesis – discrepancies in the role of SphK1
versus SphK2 in mast cells have been published. Effects of SphK1 blockade in
OVA-induced asthma has been investigated in this current project. It would be
interesting to follow up to look at the effects of SphK2 blockade in asthma.
 Role of SphK2 in Th cells homeostasis – recent studies have shown that
SphK2 appears to have a role in maintaining Th cells homeostasis, as CD4+ T
cells from SphK2 deficient mice exhibit a hyper-activated phenotype with
enhanced proliferative and Th1 cytokine-secreting capacities, and reduced
sensitivity to T-regulatory cells modulation. It will be interesting to decipher
the detailed roles of Sphk2 in the different subset of T cells.
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0.5 ml Tween 20
1000 ml PBS (1x)
Coating buffer  for ELISA
0.1 M NaHCO3, pH 8.2
TBS/1% Tween-20 for Western Blot
1 ml Tween 20




50 µl 1M NaOH
Heat to 60°C then gently mix until solution clears. Adjust pH to 7.4 with HCl.
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12% resolving gel for SDS-PAGE
Distilled water
30% bis-acrylamide




5% Stacking gel for SDS-PAGE
Distilled water
30% bis-acrylamide




Running buffer for SDS-PAGE
25 mM Tris base
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250 mM glycine, pH 8.3
0.1% SDS
Transfer buffer for SDS-PAGE




1x SDS gel-loading buffer for SDS-PAGE





Substrate solution for degranulation assay
1 mM p-nitrophenyl-N-acetyl-D-glucosominide
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